<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?DTDIdentifier.IdentifierValue -//ES//DTD journal article DTD version 5.1.0//EN//XML?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName art510.dtd?><?SourceDTD.Version 5.1.0?><?ConverterInfo.XSLTName elsevier2nlm.xsl?><?ConverterInfo.Version 1?><?origin publisher?><?FILEmeta_CMET646 xml ?><?FILEmain xml ?><?FILEgr1 jpg ?><?FILEgr2 jpg ?><?FILEgr3 jpg ?><?FILEgr4 jpg ?><?FILEgr5 jpg ?><?FILEgr6 jpg ?><?FILEmmc1 pdf ?><front><journal-meta><journal-id journal-id-type="nlm-ta">Cell Metab</journal-id><journal-title>Cell Metabolism</journal-title><issn pub-type="ppub">1550-4131</issn><issn pub-type="epub">1932-7420</issn><publisher><publisher-name>Cell Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">CMET646</article-id><article-id pub-id-type="doi">10.1016/j.cmet.2009.09.008</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Dominant Role of the p110&#x003b2; Isoform of PI3K over p110&#x003b1; in Energy Homeostasis Regulation by POMC and AgRP Neurons</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Al-Qassab</surname><given-names>Hind</given-names></name><xref rid="aff1" ref-type="aff">1</xref><xref rid="fn1" ref-type="fn">7</xref><xref rid="fn2" ref-type="fn">8</xref></contrib><contrib contrib-type="author"><name><surname>Smith</surname><given-names>Mark A.</given-names></name><xref rid="aff1" ref-type="aff">1</xref><xref rid="aff6" ref-type="aff">6</xref><xref rid="fn1" ref-type="fn">7</xref><xref rid="fn2" ref-type="fn">8</xref></contrib><contrib contrib-type="author"><name><surname>Irvine</surname><given-names>Elaine E.</given-names></name><xref rid="aff1" ref-type="aff">1</xref><xref rid="fn2" ref-type="fn">8</xref></contrib><contrib contrib-type="author"><name><surname>Guillermet-Guibert</surname><given-names>Julie</given-names></name><xref rid="aff2" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name><surname>Claret</surname><given-names>Marc</given-names></name><xref rid="aff1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Choudhury</surname><given-names>Agharul I.</given-names></name><xref rid="aff1" ref-type="aff">1</xref><xref rid="fn2" ref-type="fn">8</xref></contrib><contrib contrib-type="author"><name><surname>Selman</surname><given-names>Colin</given-names></name><xref rid="aff1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Piipari</surname><given-names>Kaisa</given-names></name><xref rid="aff1" ref-type="aff">1</xref><xref rid="fn2" ref-type="fn">8</xref></contrib><contrib contrib-type="author"><name><surname>Clements</surname><given-names>Melanie</given-names></name><xref rid="aff1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Lingard</surname><given-names>Steven</given-names></name><xref rid="aff1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Chandarana</surname><given-names>Keval</given-names></name><xref rid="aff1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Bell</surname><given-names>Jimmy D.</given-names></name><xref rid="aff3" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name><surname>Barsh</surname><given-names>Gregory S.</given-names></name><xref rid="aff4" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><name><surname>Smith</surname><given-names>Andrew J.H.</given-names></name><xref rid="aff5" ref-type="aff">5</xref></contrib><contrib contrib-type="author"><name><surname>Batterham</surname><given-names>Rachel L.</given-names></name><xref rid="aff1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Ashford</surname><given-names>Michael L.J.</given-names></name><xref rid="aff6" ref-type="aff">6</xref></contrib><contrib contrib-type="author"><name><surname>Vanhaesebroeck</surname><given-names>Bart</given-names></name><xref rid="aff2" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name><surname>Withers</surname><given-names>Dominic J.</given-names></name><email>d.withers@imperial.ac.uk</email><xref rid="aff1" ref-type="aff">1</xref><xref rid="fn2" ref-type="fn">8</xref><xref rid="cor1" ref-type="corresp">&#x02217;</xref></contrib></contrib-group><aff id="aff1"><addr-line><sup>1</sup>Centre for Diabetes and Endocrinology, Rayne Institute, University College London, London WC1E 6JJ, UK</addr-line></aff><aff id="aff2"><addr-line><sup>2</sup>Centre for Cell Signalling, Institute of Cancer, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, UK</addr-line></aff><aff id="aff3"><addr-line><sup>3</sup>Molecular Imaging Group, Medical Research Council Clinical Sciences Centre, Imperial College, London W12 0NN, UK</addr-line></aff><aff id="aff4"><addr-line><sup>4</sup>Department of Genetics, Stanford University, Stanford, CA 94305, USA</addr-line></aff><aff id="aff5"><addr-line><sup>5</sup>Gene Targeting Laboratory, The Institute of Stem Cell Research, University of Edinburgh, Edinburgh EH9 3JQ, UK</addr-line></aff><aff id="aff6"><addr-line><sup>6</sup>Biomedical Research Institute, Ninewells Hospital and Medical School, University of Dundee, Dundee DD1 9SY, UK</addr-line></aff><author-notes><corresp id="cor1"><label>&#x02217;</label>Corresponding author <email>d.withers@imperial.ac.uk</email></corresp><fn id="fn1"><label>7</label><p>These authors contributed equally to this work</p></fn><fn id="fn2"><label>8</label><p>Present address: Metabolic Signalling Group, Medical Research Council Clinical Sciences Centre, Imperial College, London W12 0NN, UK</p></fn></author-notes><pub-date pub-type="ppub"><day>04</day><month>11</month><year>2009</year></pub-date><volume>10</volume><issue>5</issue><fpage>343</fpage><lpage>354</lpage><history><date date-type="received"><day>8</day><month>2</month><year>2009</year></date><date date-type="rev-recd"><day>10</day><month>8</month><year>2009</year></date><date date-type="accepted"><day>16</day><month>9</month><year>2009</year></date></history><permissions><copyright-statement>&#x000a9; 2009 ELL &#x00026; Excerpta Medica</copyright-statement><copyright-year>2009</copyright-year><copyright-holder>Elsevier Inc.</copyright-holder><license><p>This document may be redistributed and reused, subject to <ext-link ext-link-type="uri" xlink:href="http://www.elsevier.com/wps/find/authorsview.authors/supplementalterms1.0">certain conditions</ext-link>.</p></license></permissions><abstract><title>Summary</title><p>PI3K signaling is thought to mediate leptin and insulin action in hypothalamic pro-opiomelanocortin (POMC) and agouti-related protein (AgRP) neurons, key regulators of energy homeostasis, through largely unknown mechanisms. We inactivated either p110&#x003b1; or p110&#x003b2; PI3K catalytic subunits in these neurons and demonstrate a dominant role for the latter in energy homeostasis regulation. In POMC neurons, p110&#x003b2; inactivation prevented insulin- and leptin-stimulated electrophysiological responses. POMCp110&#x003b2; null mice exhibited central leptin resistance, increased adiposity, and diet-induced obesity. In contrast, the response to leptin was not blocked in p110&#x003b1;-deficient POMC neurons. Accordingly, POMCp110&#x003b1; null mice displayed minimal energy homeostasis abnormalities. Similarly, in AgRP neurons, p110&#x003b2; had a more important role than p110&#x003b1;. AgRPp110&#x003b1; null mice displayed normal energy homeostasis regulation, whereas AgRPp110&#x003b2; null mice were lean, with increased leptin sensitivity and resistance to diet-induced obesity. These results demonstrate distinct metabolic roles for the p110&#x003b1; and p110&#x003b2; isoforms of PI3K in hypothalamic energy regulation.</p></abstract><kwd-group><kwd>HUMDISEASE</kwd></kwd-group></article-meta></front><body><sec id="sec1"><title>Introduction</title><p>Increased understanding of the molecular and cellular mechanisms that regulate whole-body energy homeostasis is needed to gain insights into the pathophysiology of obesity and for the development of effective treatments (<xref rid="bib2 bib1 bib26" ref-type="bibr">Barsh et&#x000a0;al., 2000; Barsh and Schwartz, 2002; Morton et&#x000a0;al., 2006</xref>). Hypothalamic arcuate nucleus (ARC) pro-opiomelanocortin (POMC)-expressing neurons, and agouti-related protein (AgRP)- and neuropeptide Y (NPY)-expressing neurons sense peripheral and central signals that reflect nutritional status responding to nutrients, anorexigenic peripheral hormones such as leptin and insulin, and centrally derived neuropeptides and neurotransmitters (<xref rid="bib2 bib1 bib3 bib13 bib23 bib46 bib7 bib9 bib26 bib38" ref-type="bibr">Barsh et&#x000a0;al., 2000; Barsh and Schwartz, 2002; Bewick et&#x000a0;al., 2005; Gropp et&#x000a0;al., 2005; Luquet et&#x000a0;al., 2005; Xu et&#x000a0;al., 2005a; Choudhury et&#x000a0;al., 2005; Claret et&#x000a0;al., 2007; Morton et&#x000a0;al., 2006; Smith et&#x000a0;al., 2007</xref>). Integration of these signals by POMC and AgRP/NPY neurons regulates both their neuronal activity and the expression and release of their cognate neuropeptides and other neurotransmitters, which combine to control both short- and long-term energy balance (<xref rid="bib2 bib1" ref-type="bibr">Barsh et&#x000a0;al., 2000; Barsh and Schwartz, 2002</xref>).</p><p>In these neurons, the precise intracellular signaling machinery upon which both leptin and insulin act is incompletely defined. Recent attention has focused upon class IA phosphoinositide 3-kinases (PI3Ks), which are acutely regulated by extracellular stimuli and have pleiotropic roles in cellular and organismal physiology (<xref rid="bib42" ref-type="bibr">Vanhaesebroeck et&#x000a0;al., 2005</xref>). Class IA PI3K isoforms consist of a p110 catalytic subunit (p110&#x003b1;, p110&#x003b2;, or p110&#x003b4;) constitutively bound to one of five distinct p85 regulatory subunits (<xref rid="bib42" ref-type="bibr">Vanhaesebroeck et&#x000a0;al., 2005</xref>). p110&#x003b1; and p110&#x003b2; are widely expressed, while p110&#x003b4; is predominantly expressed in leucocytes (<xref rid="bib42" ref-type="bibr">Vanhaesebroeck et&#x000a0;al., 2005</xref>). Class IA PI3Ks catalyze the synthesis of the lipid second messenger phosphatidylinositol (3,4,5)-triphosphate (PIP3), which engages downstream effectors such as the protein kinase B (PKB) pathway (<xref rid="bib37 bib42" ref-type="bibr">Shepherd et&#x000a0;al., 1998; Vanhaesebroeck et&#x000a0;al., 2005</xref>).</p><p>Evidence has implicated class IA PI3Ks in hypothalamic function, suggesting that they are a point of signaling integration for leptin and insulin action. Both hormones stimulate PI3K activity in mediobasal hypothalamic lysates and PIP3 production in POMC neurons (<xref rid="bib28 bib29" ref-type="bibr">Niswender et&#x000a0;al., 2001, 2003</xref>). Pharmacological inhibition of PI3K activity using broad-spectrum PI3K inhibitors blocks the electrophysiological effects of leptin and insulin on POMC neurons and inhibits the acute effects of leptin upon feeding and glucose homeostasis (<xref rid="bib15 bib25" ref-type="bibr">Hill et&#x000a0;al., 2008; Morton et&#x000a0;al., 2005</xref>). However, there are significant unanswered questions regarding the precise role of class IA PI3K isoforms in the hypothalamic regulation of energy homeostasis. First, the effects of specific long-term manipulation of hypothalamic expression of the two major catalytic subunits, p110&#x003b1; and p110&#x003b2;, on body weight regulation are not known. Recent pharmacological evidence using isoform-specific PI3K inhibitors and genetic studies using conditional p110&#x003b1; and p110&#x003b2; null mice and cells have started to reveal specific roles for p110&#x003b1; and p110&#x003b2; in peripheral tissues (<xref rid="bib5 bib8 bib12 bib18 bib21" ref-type="bibr">Chaussade et&#x000a0;al., 2007; Ciraolo&#x000a0;et&#x000a0;al., 2008; Graupera et&#x000a0;al., 2008; Jia et&#x000a0;al., 2008; Knight et&#x000a0;al., 2006</xref>). Therefore, these molecules may have different contributions to the regulation of neuronal function. The role of PI3K signaling in AgRP neurons in the regulation of energy homeostasis has also not been determined. In the context of&#x000a0;ongoing PI3K drug development, a key question is which of&#x000a0;the many PI3K isoforms should be targeted to achieve specific therapeutic benefit (<xref rid="bib24 bib45" ref-type="bibr">Marone et&#x000a0;al., 2008; Wymann et&#x000a0;al., 2003</xref>). We therefore inactivated p110&#x003b1; and p110&#x003b2; in POMC or AgRP neurons to determine the role of these kinases in energy homeostasis.</p></sec><sec id="sec2"><title>Results</title><sec id="sec2.1"><title>Generation of Mice Lacking p110&#x003b1; or p110&#x003b2; in POMC and AgRP Neurons</title><p>Mice with floxed alleles of either p110&#x003b1; (<italic>Pik3ca</italic>) or p110&#x003b2; (<italic>Pik3cb</italic>) (<xref rid="bib12 bib14" ref-type="bibr">Graupera et&#x000a0;al., 2008; Guillermet-Guibert et&#x000a0;al., 2008</xref>) were crossed with mice that express Cre recombinase in POMC or AgRP neurons (<xref rid="bib7 bib9 bib46 bib47" ref-type="bibr">Choudhury et&#x000a0;al., 2005; Claret et&#x000a0;al., 2007; Xu et&#x000a0;al., 2005a, 2005b</xref>) to generate POMCp110 null and AgRPp110 null mice for each isoform and relevant control strains. The floxed alleles of p110&#x003b1; and p110&#x003b2; were designed to preserve the signaling stoichiometry of the p85/p110 PI3K signaling complexes (<xref rid="bib12 bib14" ref-type="bibr">Graupera et&#x000a0;al., 2008; Guillermet-Guibert et&#x000a0;al., 2008</xref>). In the brain, genetic inactivation of p110&#x003b1; or p110&#x003b2; was restricted to the hypothalamus, as determined by PCR analysis of the recombination event (<xref rid="fig1" ref-type="fig">Figures 1</xref>A and 1B). We did not detect Cre recombinase expression in the dentate gyrus or nucleus tractus solitarus (data not shown). Hypothalamic p110&#x003b1; lipid kinase activity in POMC- and AgRPp110&#x003b1; null mice (<xref rid="fig1" ref-type="fig">Figure&#x000a0;1</xref>C) and p110&#x003b2; activity in POMC- and AgRPp110&#x003b2; null mice (<xref rid="fig1" ref-type="fig">Figure&#x000a0;1</xref>D) was reduced, but expression of p85 was unaltered (<xref rid="fig1" ref-type="fig">Figures 1</xref>C and 1D). Expression of p110&#x003b1;, p110&#x003b2;, and p85 in muscle, liver, and fat was also equivalent in mutant and control mice (data not shown).</p></sec><sec id="sec2.2"><title>Inactivation of p110&#x003b1; or p110&#x003b2; in POMC and AgRP Neurons Does Not Lead to Observable Alterations in Cell Body Organization and Number</title><p>PI3K signaling plays key roles in cellular function, but mutant mice did not show alterations in the location, population size,&#x000a0;or somatic dimensions of POMC (see <xref rid="app2" ref-type="sec">Figures S1</xref>A&#x02013;S1H available online) or AgRP neurons (<xref rid="app2" ref-type="sec">Figures S2</xref>A&#x02013;S2H) compared to control mice. No differences were observed in basic neuronal&#x000a0;biophysical properties in the mutant mice, although the resting&#x000a0;membrane potential of POMCp110&#x003b1; null neurons was&#x000a0;slightly hyperpolarized compared to control POMC neurons,&#x000a0;with a concomitant reduction in firing rate (<xref rid="app2" ref-type="sec">Table S1</xref>). However, this change in firing rate did not affect basal peptide release, as hypothalamic explant studies showed that release of alpha melanocyte-stimulating hormone (&#x003b1;-MSH) and AgRP in POMC- and AgRP-targeted mutants, respectively, was equivalent to control mice (<xref rid="app2" ref-type="sec">Figures S3</xref>A&#x02013;S3D). The POMC promoter also drives Cre recombinase expression in anterior pituitary corticotrophs, but corticosterone levels in all four mutant lines were equivalent to control mice (<xref rid="app2" ref-type="sec">Figures S4</xref>A&#x02013;S4D).</p></sec><sec id="sec2.3"><title>POMCp110&#x003b2; Null Mice Display Increased Food Intake, Adiposity, and Sensitivity to a High-Fat Diet</title><p>POMCp110&#x003b2; null mice on standard chow displayed normal total&#x000a0;body mass but an increased fat mass and fasting hyperleptinemia (<xref rid="fig2" ref-type="fig">Figures 2</xref>A, 2C, and 2D). Magnetic resonance imaging (MRI) at 24&#x000a0;weeks of age confirmed increased total body adiposity (fat mass per body weight, POMCp110&#x003b2; null 16.2% &#x000b1; 1.2%&#x000a0;versus control 9.5% &#x000b1; 1.3%, n &#x0003d; 5, p &#x0003c; 0.01). POMCp110&#x003b1; null mice, in contrast, displayed normal body weight, fat mass, and leptin levels (<xref rid="fig2" ref-type="fig">Figures 2</xref>B&#x02013;2D). POMCp110&#x003b2; null mice, but not POMCp110&#x003b1; null mice, displayed increased food intake, both daily and following an overnight fast (<xref rid="fig2" ref-type="fig">Figures 2</xref>E&#x02013;2G), and increased linear growth (<xref rid="app2" ref-type="sec">Figures&#x000a0;S5</xref>A and S5B). Resting metabolic rate (RMR) and sensitivity to the&#x000a0;peripherally administered MC3/4R agonist melanotan II (MT-II) were normal&#x000a0;in both POMCp110&#x003b1; null and POMCp110&#x003b2; null mice (<xref rid="app2" ref-type="sec">Figures S5</xref>C&#x02013;S5F). On a high-fat diet (HFD), both POMCp110&#x003b1; null and POMCp110&#x003b2; null mice displayed increased body weight, adiposity, and hyperleptinemia, compared to controls (<xref rid="fig2" ref-type="fig">Figures 2</xref>H&#x02013;2J).</p></sec><sec id="sec2.4"><title>AgRPp110&#x003b2; Null Mice Are Hypophagic, Lean, and Resistant to Diet-Induced Obesity</title><p>Body weight (<xref rid="fig3" ref-type="fig">Figure&#x000a0;3</xref>A), fat mass (<xref rid="fig3" ref-type="fig">Figure&#x000a0;3</xref>C), and leptin levels (<xref rid="fig3" ref-type="fig">Figure&#x000a0;3</xref>D) were significantly lower in AgRPp110&#x003b2; null mice. Food intake ad libitum and following an overnight fast was reduced in AgRPp110&#x003b2; null mice (<xref rid="fig3" ref-type="fig">Figures 3</xref>E and 3G). In contrast, AgRPp110&#x003b1; null mice displayed no significant alterations within these parameters (<xref rid="fig3" ref-type="fig">Figures 3</xref>B&#x02013;3F). RMR and sensitivity to MT-II were normal in both AgRPp110&#x003b1; null and AgRPp110&#x003b2; null mice&#x000a0;(<xref rid="app2" ref-type="sec">Figures S6</xref>A&#x02013;S6D). On HFD, AgRPp110&#x003b2; null, but not AgRPp110&#x003b1; null, mice displayed a significant reduction in body weight, fat mass, and leptin levels, compared to controls (<xref rid="fig3" ref-type="fig">Figures&#x000a0;3</xref>H&#x02013;3J).</p></sec><sec id="sec2.5"><title>Leptin-Mediated Suppression of Food Intake Is Impaired in POMCp110&#x003b2; Null Mice but Enhanced in AgRPp110&#x003b2; Null Mice</title><p>In POMCp110&#x003b2; null mice, suppression of food intake by leptin administered into the third cerebral ventricle (i.c.v.) was equivalent to control mice at 4 hr but blunted at 24 hr postinjection (<xref rid="fig4" ref-type="fig">Figure&#x000a0;4</xref>A). Conversely, AgRPp110&#x003b2; null mice had increased sensitivity to i.c.v. leptin at both 4 and 24 hr postinjection, compared to controls (<xref rid="fig4" ref-type="fig">Figure&#x000a0;4</xref>B). Inactivating p110&#x003b1; in POMC or AgRP neurons did not affect the response to leptin (<xref rid="app2" ref-type="sec">Figures S7</xref>A and S7B).</p></sec><sec id="sec2.6"><title>Hypothalamic Neuropeptide mRNA Expression and Glucose Homeostasis in p110 Mutant Mice</title><p>A small but significant reduction in <italic>Pomc</italic> mRNA was detectable in fasted POMCp110&#x003b2; null mice, while <italic>Agrp</italic> and <italic>Npy</italic> mRNA were unaltered (<xref rid="fig4" ref-type="fig">Figure&#x000a0;4</xref>C). <italic>Npy</italic> mRNA was reduced in AgRPp110&#x003b2;null mice, while <italic>Pomc</italic> and <italic>Agrp</italic> mRNA were unchanged (<xref rid="fig4" ref-type="fig">Figure&#x000a0;4</xref>D). No differences in the expression of <italic>Pomc</italic>, <italic>Agrp</italic>, and <italic>Npy</italic> mRNA were detected in POMCp110&#x003b1; null and AgRPp110&#x003b1; null mice (<xref rid="app2" ref-type="sec">Figures S7</xref>C and S7D). Leptin also recruits the janus kinase/signal transducer and activator of transcription (JAK/STAT) pathway to modulate the expression of arcuate neuropeptides. However, we found no alteration of leptin-stimulated STAT3 phosphorylation in POMC or AgRP neurons lacking p110&#x003b2; (percent leptin-stimulated POMC or AgRP neuron pSTAT3: control, 46% &#x000b1; 6% versus POMC p110&#x003b2; null, 42% &#x000b1; 5%, p &#x0003d; N.S.; control 54% &#x000b1; 5% versus AgRP p110&#x003b2; null 67%&#x000a0;&#x000b1; 9% p &#x0003d; N.S., n &#x0003d; 3 animals per genotype and <xref rid="app2" ref-type="sec">Figure&#x000a0;S8</xref>). POMC and AgRP neurons have been implicated in the central regulation of glucose homeostasis (<xref rid="bib22 bib32" ref-type="bibr">Konner et&#x000a0;al., 2007; Parton et&#x000a0;al., 2007</xref>), but no alterations were found in fasting glucose levels, glucose tolerance, and fasting insulin levels in all four mutant lines (<xref rid="app2" ref-type="sec">Figures S9</xref>A&#x02013;S9H).</p></sec><sec id="sec2.7"><title>p110&#x003b2; Is Required for Leptin-Induced Depolarization of POMC Neurons</title><p>We next used electrophysiological analysis to investigate neuronal responses to leptin and insulin in POMCp110&#x003b2; null and POMCp110&#x003b1; null mice. Consistent with previous observations (<xref rid="bib7 bib9 bib10 bib34" ref-type="bibr">Choudhury et&#x000a0;al., 2005; Claret et&#x000a0;al., 2007; Cowley et&#x000a0;al., 2001; Plum et&#x000a0;al., 2006</xref>), a subpopulation of control POMC neurons (6 of 21) responded to locally applied leptin (50 nM) by long-lasting (&#x0003e;1 hr) membrane depolarization (<xref rid="fig5" ref-type="fig">Figure&#x000a0;5</xref>A), an action significant for the recorded population (n &#x0003d; 21, p &#x0003c; 0.05; <xref rid="tbl1" ref-type="table">Table 1</xref>). Although leptin depolarization of POMC neurons could be observed at resting membrane potentials (Vm) of approximately &#x02212;50 mV, the magnitude of response was greater at more hyperpolarized Vm (r<sup>2</sup> &#x0003d; 0.63, n &#x0003d; 21, p &#x0003c; 0.0001; <xref rid="app2" ref-type="sec">Figure&#x000a0;S10</xref>A). As previously reported, the majority of control POMC neurons were unresponsive to leptin (<xref rid="tbl1" ref-type="table">Table 1</xref> and <xref rid="app2" ref-type="sec">Figure&#x000a0;S10</xref>B).</p><p>As POMCp110&#x003b2; null mice displayed reduced sensitivity to leptin, we examined the effect of genetic inactivation of specific PI3K catalytic subunit isoforms on leptin-mediated POMC excitability. In mice aged 8&#x02013;16 weeks, leptin depolarized (n &#x0003d; 13, p &#x0003c; 0.05) the POMCp110&#x003b1; null neuronal population and increased their spike firing frequency (<xref rid="fig5" ref-type="fig">Figure&#x000a0;5</xref>B and <xref rid="tbl1" ref-type="table">Table 1</xref>), in agreement with the unchanged leptin sensitivity observed in&#x000a0;vivo. In contrast, leptin did not depolarize POMCp110&#x003b2; null neurons, and indeed many POMCp110&#x003b2; null neurons (7 of 17) exhibited long-lasting hyperpolarization following leptin application (<xref rid="fig5" ref-type="fig">Figure&#x000a0;5</xref>C, <xref rid="tbl1" ref-type="table">Table 1</xref>). Subsequently, in a separate series of experiments on age- (7- and 18-week-old) and sex-matched POMCp110&#x003b2; null mutant mice, we first showed that food intake was elevated at both 7 and 18 weeks of age. Irrespective of age or metabolic phenotype, subsequent electrophysiological recordings from POMCp110&#x003b2; null neurons demonstrated that there were no alterations to POMC neuron resting membrane potential, spike firing frequency, or input resistance in comparison to littermate control POMC neurons (<xref rid="app2" ref-type="sec">Table S2</xref>). Furthermore, these POMCp110&#x003b2; null neurons exhibited the same altered response to leptin (i.e., conversion of depolarization to hyperpolarization) that was significantly different from the leptin-mediated excitation of control POMC neurons.</p><p>To exclude the possibility that compensatory changes associated with chronic ablation of p110&#x003b2; expression were responsible for this altered leptin response, in separate experiments on control POMC neurons, the selective p110&#x003b2; inhibitor TGX-221 (1 &#x003bc;M) (<xref rid="bib17" ref-type="bibr">Jackson et&#x000a0;al., 2005</xref>) was added to the internal pipette solution. Following a minimum of 10 min of intracellular dialysis, leptin (50&#x000a0;nM) application did not excite TGX-221-treated POMC neurons (n &#x0003d; 11, N.S.; <xref rid="fig5" ref-type="fig">Figure&#x000a0;5</xref>D and <xref rid="tbl1" ref-type="table">Table 1</xref>). On one occasion, a large leptin-mediated hyperpolarization was&#x000a0;observed, which was reversibly occluded by bath-applied tolbutamide, indicating the likely involvement of ATP-sensitive K<sup>&#x0002b;</sup> (K<sub>ATP</sub>) channels in this hyperpolarizing response (<xref rid="app2" ref-type="sec">Figure&#x000a0;S10</xref>C). Overall, these electrophysiological outcomes reflect the decreased leptin sensitivity found in POMCp110&#x003b2; null mice in&#x000a0;vivo.</p></sec><sec id="sec2.8"><title>Inactivation of p110&#x003b1; or p110&#x003b2; in POMC Neurons Prevents Insulin-Induced Hyperpolarization</title><p>POMC neurons are also targets for insulin action, and consistent with previous reports (<xref rid="bib7 bib9 bib15 bib22 bib35" ref-type="bibr">Choudhury et&#x000a0;al., 2005; Claret et&#x000a0;al., 2007; Hill et&#x000a0;al., 2008; Konner et&#x000a0;al., 2007; Plum et&#x000a0;al., 2007</xref>), a subpopulation of control POMC neurons (12 of 19) responded to insulin by long-lasting (&#x0003e;1 hr) hyperpolarization (<xref rid="tbl1" ref-type="table">Table 1</xref> and <xref rid="fig5" ref-type="fig">Figure&#x000a0;5</xref>E). Subsequent bath application of tolbutamide (200 &#x003bc;M) reversed this response (<xref rid="fig5" ref-type="fig">Figure&#x000a0;5</xref>E). The remaining neurons were unresponsive to insulin (50 nM, <xref rid="app2" ref-type="sec">Figure&#x000a0;S10</xref>D). Neither POMCp110&#x003b1; null (n &#x0003d; 8, N.S.; <xref rid="fig5" ref-type="fig">Figure&#x000a0;5</xref>F) nor POMCp110&#x003b2; null (n &#x0003d; 9, N.S.; <xref rid="fig5" ref-type="fig">Figure&#x000a0;5</xref>G) neurons responded to insulin (<xref rid="tbl1" ref-type="table">Table 1</xref>), suggesting that both p110 isoforms contribute to the action of insulin in POMC neurons. Acute pharmacological inhibition of p110&#x003b2; by TGX-221 (1 &#x003bc;M) also prevented insulin hyperpolarization of POMC neurons (n &#x0003d; 8, N.S.; <xref rid="fig5" ref-type="fig">Figure&#x000a0;5</xref>H and <xref rid="tbl1" ref-type="table">Table 1</xref>). In addition, the pan-PI3K/mTOR inhibitor, PI-103 (100 nM), prevented insulin-evoked POMC neuron hyperpolarization (n &#x0003d; 7; <xref rid="fig5" ref-type="fig">Figure&#x000a0;5</xref>I and <xref rid="tbl1" ref-type="table">Table 1</xref>).</p><p>Thus, leptin and insulin induce opposing electrical responses in subsets of POMC neurons, and both outcomes require the p110&#x003b2; subunit of PI3K. This result could be due to differential expression of the hormone receptors and/or of the p110&#x003b1; and p110&#x003b2; subunits in the POMC neuron population. We attempted to resolve this issue in two ways, by electrophysiological analysis of the actions of sequentially applied leptin and insulin to single POMC neurons and by immunohistochemical detection of POMC neurons in mice expressing lacZ from either the p110&#x003b1; or the p110&#x003b2; loci. Sequential leptin- and insulin-induced depolarization and hyperpolarization, respectively, were observed in three of eight recordings, indicating functional colocalization of receptors in a subpopulation of POMC neurons (<xref rid="fig5" ref-type="fig">Figure&#x000a0;5</xref>J and <xref rid="app2" ref-type="sec">Figure&#x000a0;S11</xref>A). However, some POMC neurons only responded to leptin (two of eight), with the remainder (three of eight) not responding to either hormone. Note that we did not observe POMC neurons that only responded to insulin. Furthermore, 47% (&#x000b1;4.3, n &#x0003d; 3) of POMC neurons expressed p110&#x003b2; and 55% (&#x000b1;5.7, n &#x0003d; 3) p110&#x003b1; (<xref rid="app2" ref-type="sec">Figures S11</xref>B and S11C). Accordingly, some POMC neurons must express both hormone receptors and p110 subunits, whereas the expression of p110&#x003b2; alone may explain why some POMC neurons respond only to leptin.</p></sec><sec id="sec2.9"><title>p110&#x003b1; and p110&#x003b2; Are Required for Insulin-Induced Depolarization of AgRP Neurons</title><p>Consistent with our previous data (<xref rid="bib9" ref-type="bibr">Claret et&#x000a0;al., 2007</xref>), leptin (50&#x000a0;nM) did not affect Vm or spike frequency in control AgRP (n&#x000a0;&#x0003d; 7, N.S., <xref rid="tbl1" ref-type="table">Table 1</xref>, <xref rid="fig6" ref-type="fig">Figure&#x000a0;6</xref>A), or AgRPp110&#x003b1; null (n &#x0003d; 7, N.S.; <xref rid="tbl1" ref-type="table">Table 1</xref>, <xref rid="fig6" ref-type="fig">Figure&#x000a0;6</xref>B), or AgRPp110&#x003b2; null (n &#x0003d; 7, N.S.; <xref rid="tbl1" ref-type="table">Table 1</xref>, <xref rid="fig6" ref-type="fig">Figure&#x000a0;6</xref>C) neurons. In contrast, insulin (50 nM) caused a long-lasting (&#x0003e;1 hr) depolarization of a subpopulation (4 of 13) of control AgRP neurons (<xref rid="fig6" ref-type="fig">Figure&#x000a0;6</xref>D), an action significant for the recorded population (n &#x0003d; 13, p &#x0003c; 0.05; <xref rid="tbl1" ref-type="table">Table 1</xref>). As observed for leptin on POMC neurons, the depolarization induced by insulin was greater at more hyperpolarized Vm (r<sup>2</sup> &#x0003d; 0.65, p &#x0003c; 0.0001, n &#x0003d; 13, <xref rid="app2" ref-type="sec">Figure&#x000a0;S12</xref>A). Insulin did not change the excitability of the remaining AgRP neurons (recording periods up to 1 hr; <xref rid="app2" ref-type="sec">Figure&#x000a0;S12</xref>B). We next tested whether inactivation of p110&#x003b1; or p110&#x003b2; prevented or modified insulin action on AgRP neurons. Surprisingly, insulin hyperpolarized both AgRPp110&#x003b1; null (n &#x0003d; 7, p &#x0003c; 0.05; <xref rid="fig6" ref-type="fig">Figure&#x000a0;6</xref>E) and AgRPp110&#x003b2; null (n &#x0003d; 11, p &#x0003c; 0.05; <xref rid="fig6" ref-type="fig">Figure&#x000a0;6</xref>F) neurons, and these responses were reversed by tolbutamide. In addition, the pan-PI3K inhibitor wortmannin (100 nM present in the internal recording solution), although having no effect per se on Vm, also resulted in insulin hyperpolarizing control AgRP neurons (n &#x0003d; 10, p &#x0003c; 0.05; <xref rid="tbl1" ref-type="table">Table 1</xref>), a response occluded, reversibly, by tolbutamide (<xref rid="fig6" ref-type="fig">Figure&#x000a0;6</xref>G).</p></sec></sec><sec id="sec3"><title>Discussion</title><p>Hypothalamic PI3K signaling mechanisms have received significant attention and may act as a point of convergence for leptin and insulin action in POMC and AgRP neurons. However, studies to date have indirectly used genetics to manipulate PI3K signaling or have used inhibitors such as wortmannin and LY294002, which inhibit all PI3K isoforms and several other kinases such as mTOR, which has also been implicated in hypothalamic function. Both strategies also do not enable discrimination between the distinct PI3K isoforms. Using newly created floxed alleles of p110&#x003b1; and p110&#x003b2;, which preserve the stoichiometry of the class IA PI3K signaling network (<xref rid="bib12 bib14" ref-type="bibr">Graupera et&#x000a0;al., 2008; Guillermet-Guibert et&#x000a0;al., 2008</xref>), our study reveals a dominant role for p110&#x003b2; in POMC and AgRP neurons.</p><p>Our studies (summarized in <xref rid="app2" ref-type="sec">Table S3</xref>) show that POMCp110&#x003b2; null mice display hyperphagia, increased adiposity, and hyperleptinemia on normal chow diet and increased sensitivity to high-fat feeding. Furthermore, POMC neurons, in which p110&#x003b2; was genetically or pharmacologically inhibited, were electrically unresponsive to insulin and leptin. Indeed, the inability of leptin to excite POMCp110&#x003b2; null neurons (and instead hyperpolarize them) was correlated with elevated food intake in POMCp110&#x003b2; null mice, which was also not fully suppressed by centrally administered leptin. POMCp110&#x003b2; null mice had a reduction in POMC mRNA levels consistent with reports suggesting that the modulation of POMC transcription by leptin is dependent on PI3K-controlled regulation of forkhead box O1 (FoxO1) activity (<xref rid="bib19 bib20" ref-type="bibr">Kim et&#x000a0;al., 2006; Kitamura et&#x000a0;al., 2006</xref>). Thus, inactivation of p110&#x003b2; in POMC neurons may result in an overall reduction in the expression and release of &#x003b1;-MSH, which may make these mice more likely to store excess energy as fat on a standard chow diet and more susceptible to weight gain when exposed to a HFD. In contrast, POMCp110&#x003b1; null mice did not display&#x000a0;a significant body weight phenotype under standard chow conditions but did develop increased adiposity and hyperleptinemia when exposed to a HFD, indicating an as yet undefined role for POMCp110&#x003b1; in response to excess caloric intake. Genetic inactivation of p110&#x003b1; prevented insulin-induced hyperpolarization, although it did not prevent leptin-mediated depolarization of POMC neurons. The precise roles of insulin action on this neuronal type have not been fully elucidated, but as deletion of the insulin receptor on POMC neurons is not reported to cause a metabolic phenotype (<xref rid="bib22" ref-type="bibr">Konner et&#x000a0;al., 2007</xref>), the lack of phenotype in POMCp110&#x003b1; mice is consistent with this observation. Blockade of insulin-induced hyperpolarization in POMC neurons may therefore not translate to abnormalities in metabolism.</p><p>Previous mouse genetic evidence has also linked PI3K signaling in POMC neurons with the regulation of energy homeostasis. However, due to the nature of the various approaches, there has been some discordance in the results. For example, PIP3 production was elevated in POMC neurons in which the phosphatase and tensin homolog (Pten), a PIP3 phosphatase, was specifically deleted, and these mice were hyperphagic and displayed diet-sensitive obesity (<xref rid="bib34" ref-type="bibr">Plum et&#x000a0;al., 2006</xref>). Mice harboring combined POMC-selective deletion of p85&#x003b1; with&#x000a0;a global deletion of p85&#x003b2; subunit were unresponsive to insulin and leptin in electrophysiological studies (<xref rid="bib15" ref-type="bibr">Hill et&#x000a0;al., 2008</xref>). These mice had abnormalities in both short-term feeding and acute responses to leptin but had no long-term disorder in energy homeostasis. However, POMC-specific deletion of <italic>Pten</italic> or p85 is likely to have effects beyond PI3K signaling. Deletion of <italic>Pten</italic> has a profound anatomical impact on POMC neurons, and the role of both Pten's lipid phosphatase (i.e., PI3K-dependent) and protein phosphatase activities in regulating leptin action suggest that this model may have additional abnormalities (<xref rid="bib27 bib34" ref-type="bibr">Ning et&#x000a0;al., 2006; Plum et&#x000a0;al., 2006</xref>). Deletion of the p85 regulatory subunits often leads to increased PI3K signaling (<xref rid="bib42" ref-type="bibr">Vanhaesebroeck et&#x000a0;al., 2005</xref>). For example, the p85&#x003b2; global null mouse has improved insulin and potentially leptin action and is smaller than control littermates (<xref rid="bib40" ref-type="bibr">Ueki et&#x000a0;al., 2002</xref>). Furthermore, tyrosine phosphorylation of IRS2 is upregulated in these mice, which may impact upon long-term energy balance. p85&#x003b1; and p85&#x003b2; subunits also have signaling roles independent of&#x000a0;their association with p110 catalytic subunits, and therefore full deletion of p85 subunits may lead to effects independent of PI3K catalytic activity (<xref rid="bib31" ref-type="bibr">Okkenhaug and Vanhaesebroeck, 2001</xref>).</p><p>Like POMC neurons, AgRP neurons are targets for leptin and insulin action, but the role of PI3K in these neurons is largely unknown. Mice in which p110&#x003b2;, but not p110&#x003b1;, was inactivated in AgRP neurons display an age-dependent lean phenotype with reduced adiposity, hypoleptinemia, and resistance to diet-induced obesity (<xref rid="app2" ref-type="sec">Table S3</xref>). This phenotype may be surprising, given that disruption of leptin receptor expression specifically in AgRP neurons results in mild obesity, suggesting that loss of leptin action via PI3K signaling might result in a similar phenotype. However, leptin withdrawal, rather than administration, has been described to activate PI3K and accumulate PIP3 in AgRP neurons (<xref rid="bib47" ref-type="bibr">Xu et&#x000a0;al., 2005b</xref>). Thus reducing PI3K activity in AgRP neurons may result in these cells behaving as if they are exposed to increased leptin levels, physiologically resulting in a lean phenotype (<xref rid="bib47" ref-type="bibr">Xu et&#x000a0;al., 2005b</xref>). However, consistent with our previous study (<xref rid="bib9" ref-type="bibr">Claret et&#x000a0;al., 2007</xref>), leptin did not change the excitability of control and p110&#x003b1; or p110&#x003b2; null AgRP neurons. Although others have observed leptin-mediated hyperpolarization of a subpopulation of rat AgRP-expressing neurons (<xref rid="bib41" ref-type="bibr">van den Top et&#x000a0;al., 2004</xref>), methodological and species differences may explain these discrepancies. Nevertheless, insulin excites AgRP neurons under our recording conditions (<xref rid="bib9" ref-type="bibr">Claret et&#x000a0;al., 2007</xref>), but in p110&#x003b2;- or p110&#x003b1;-deleted as well as pharmacologically PI3K-inhibited AgRP neurons, insulin inhibits the excitability of these neurons. The net effect of this alteration would be to reduce insulin-induced depolarization and consequently decrease the release of AgRP and NPY with a resultant attenuation in orexigenic output. Mice lacking either <italic>Agrp</italic> or <italic>Npy</italic> have mild body weight phenotypes or reduced feeding after a fast (<xref rid="bib33 bib44" ref-type="bibr">Patel et&#x000a0;al., 2006; Wortley et&#x000a0;al., 2005</xref>). <italic>Npy</italic> mRNA was reduced in the hypothalamus of AgRPp110&#x003b2; null mice, therefore potentially contributing to the lean phenotype observed in these mice. STAT3 signaling is reported to play a major role in mediating leptin-induced alteration in neuropeptide expression including <italic>Agrp</italic> and <italic>Npy</italic>. However, leptin-stimulated STAT3 phosphorylation was equivalent in both AgRP and AgRPp110&#x003b2; null neurons and is unlikely to underlie the lean phenotype in these mice.</p><p>An important issue arising from the electrophysiological studies pertains to the mechanisms by which leptin and insulin, through the increased production of a signaling molecule in common (i.e., PIP3), produce opposing electrical responses in POMC neurons. Approximately half of POMC neurons express p110&#x003b1; or p110&#x003b2;. However, due to the lack of suitable reagents, we have not been able to establish the coincidence of expression of these subunits in POMC neurons. The finding that leptin, but not insulin, alone can modify electrical activity of some POMC neurons could be explained either by selective expression of the p110&#x003b2; subunit alone or the leptin receptor exhibiting selective coupling to this subunit. In contrast, it is less likely that p110&#x003b1; is expressed in a subpopulation of POMC neurons independently from p110&#x003b2;, as insulin responses were only observed in neurons that also responded to leptin and insulin-mediated POMC neuron hyperpolarization required the presence of both p110 subunits. The inability of both leptin and insulin to modulate the electrical activity of some POMC neurons may indicate that they lack functional receptors for either hormone (<xref rid="bib6 bib11 bib16" ref-type="bibr">Cheung et&#x000a0;al., 1997; Elias et&#x000a0;al., 1999; Huo et&#x000a0;al., 2009</xref>). Alternatively, these unresponsive POMC neurons may lack the p110&#x003b2; subunit, although we have no way of determining whether the p110&#x003b1; subunit is present or not in these neurons. The finding that insulin-mediated hyperpolarization of POMC, and depolarization of AgRP, neurons was ablated by removal of either p110&#x003b1; or p110&#x003b2; may indicate that both catalytic subunits are required to generate sufficient PIP3 to pass some threshold level for downstream signaling. Such a scenario has been proposed previously whereby p110&#x003b2; activity serves to set the threshold for p110&#x003b1; activation (<xref rid="bib8 bib18 bib21" ref-type="bibr">Ciraolo et&#x000a0;al., 2008; Jia et&#x000a0;al., 2008; Knight et&#x000a0;al., 2006</xref>). Nevertheless, there must be divergent downstream signaling pathways activated following a rise in PIP3 to explain the opposing PI3K-dependent electrical responses seen in some POMC neurons to leptin and insulin, which results in either K<sub>ATP</sub> channel activation (hyperpolarization) or the activation of an, as yet, ill-defined putative nonselective cation channel (depolarization). The insulin-mediated hyperpolarization of AgRP neurons observed on genetic deletion of either p110 subunit, or by pharmacological inhibition of PI3K activity, indicates the presence of a separate, possibly PIP3-independent, pathway leading to activation of K<sub>ATP</sub> channels that is normally occluded by PI3K signaling in these neurons.</p><p>Recent studies have begun to link different physiological properties with the various PI3K catalytic subunit isoforms (<xref rid="bib36" ref-type="bibr">Shaywitz et&#x000a0;al., 2008</xref>). For example, we have demonstrated that p110&#x003b1;, and not p110&#x003b2;, plays a key role in developmental angiogenesis (<xref rid="bib12" ref-type="bibr">Graupera et&#x000a0;al., 2008</xref>) and have provided evidence that p110&#x003b2; lies downstream of G protein-coupled receptors (GPCRs) in fibroblasts and macrophages and is not acutely regulated by receptor tyrosine kinases (<xref rid="bib14" ref-type="bibr">Guillermet-Guibert et&#x000a0;al., 2008</xref>). p110&#x003b1; appears to predominantly mediate the effects of insulin and other receptor tyrosine kinases in some tissues, although here we show that p110&#x003b2; is equally important for insulin-mediated changes in electrical excitability of hypothalamic neurons. At present, it is unknown which isoform is responsible for leptin-mediated PI3K actions in tissues, although in this study p110&#x003b2; plays the principal role in POMC neurons. Recently it has been demonstrated that liver-specific deletion of p110&#x003b2; abrogates insulin action in this tissue (<xref rid="bib18" ref-type="bibr">Jia et&#x000a0;al., 2008</xref>). Interestingly, these mice also displayed hyperleptinemia and dysregulation of key hepatic metabolic genes (<xref rid="bib18" ref-type="bibr">Jia et&#x000a0;al., 2008</xref>). Furthermore, these studies suggested that p110&#x003b2; lipid kinase activity is not able to direct PKB phosphorylation but plays a role in S6 kinase-1 activation (<xref rid="bib18" ref-type="bibr">Jia et&#x000a0;al., 2008</xref>), an event that has recently been implicated in hypothalamic regulation of energy homeostasis (<xref rid="bib43" ref-type="bibr">Woods et&#x000a0;al., 2008</xref>). The predominance of p110&#x003b2; signaling, perhaps recruited by GPCRs rather than by IRS2-associated p110&#x003b1; signaling, in POMC and AgRP neurons is consistent with our findings that mice lacking <italic>Irs2</italic> in these cell types have no energy homeostasis phenotype (<xref rid="bib7" ref-type="bibr">Choudhury et&#x000a0;al., 2005</xref>). It is also possible that p110&#x003b2; is playing a scaffolding role in signaling (<xref rid="bib8 bib18" ref-type="bibr">Ciraolo et&#x000a0;al., 2008; Jia et&#x000a0;al., 2008</xref>) in POMC and AgRP neurons and that this may mediate some of the observed effects of deleting this molecule in these neurons. These considerations may also underlie the ability of PI3K to mediate opposing responses to leptin and insulin in POMC neurons and affect an entirely opposite outcome with respect to excitability observed on the loss or inhibition of one of the isoforms. Furthermore, if these PI3K isoforms are capable of being modulated independently by extrinsic factors, this may profoundly affect the cellular outcome to leptin and insulin and have a major impact on energy homeostasis.</p><p>In summary, our studies have revealed an isoform-specific role for class IA PI3K signaling in POMC neurons and demonstrate for the first time the key role of class IA PI3K signaling in AgRP neurons in the long-term regulation of energy homeostasis.</p></sec><sec sec-type="materials-methods" id="sec4"><title>Experimental Procedures</title><sec id="sec4.1"><title>Mice and Animal Care</title><p>The generation and genotyping of <italic>POMC-Cre</italic> and <italic>AgRP-Cre</italic> (<xref rid="bib7 bib9 bib46 bib47" ref-type="bibr">Choudhury et&#x000a0;al., 2005; Claret et&#x000a0;al., 2007; Xu et&#x000a0;al., 2005a, 2005b</xref>), <italic>Pik3ca<sup>flox</sup></italic> or p110&#x003b1;<sup>flox</sup> (<xref rid="bib12" ref-type="bibr">Graupera et&#x000a0;al., 2008</xref>), and <italic>Pik3cb<sup>flox</sup></italic> or p110&#x003b2;<sup>flox</sup> (<xref rid="bib14" ref-type="bibr">Guillermet-Guibert et&#x000a0;al., 2008</xref>) mice have been previously described. Mice with floxed alleles were intercrossed with the indicated <italic>Cre</italic>-expressing transgenic mice to generate compound heterozygote mice. These double heterozygote mice were then intercrossed with <italic>lox<sup>&#x0002b;/&#x02212;</sup></italic> mice to obtain WT, <italic>flox<sup>&#x0002b;/&#x0002b;</sup></italic>, <italic>Cre</italic>, and <italic>Cre/flox<sup>&#x0002b;/&#x0002b;</sup></italic> mice for each line. To generate mice lacking floxed alleles but expressing GFP or YFP in cells harboring the deletion event, mice were intercrossed with <italic>Z/EG</italic> (<xref rid="bib30" ref-type="bibr">Novak et&#x000a0;al., 2000</xref>) or <italic>Rosa26YFP</italic> (<xref rid="bib39" ref-type="bibr">Srinivas et&#x000a0;al., 2001</xref>) indicator mice and bred to homozygosity for the floxed allele. For detection of Cre-mediated excision of exons 18 and 19 of p110&#x003b1; in the hypothalami of AgRPp110&#x003b1; null and POMCp110&#x003b1; null mice, genomic DNA was isolated from the hypothalamus, cortex, and other tissues of control and mutant mice as previously described (<xref rid="bib7" ref-type="bibr">Choudhury et&#x000a0;al., 2005</xref>). The generation of a 544 bp DNA product following PCR with primers ACACACTGCATCAATGGC and GCTGCCGAATTGCTAGGTAAGC is indicative of excision of the floxed p110&#x003b1; exons in AgRP and POMC neurons of AgRPp110&#x003b1; null and POMCp110&#x003b1; null mice, respectively. For detection of Cre-mediated excision of exons 21 and 22 of the p110&#x003b2; catalytic domain in the hypothalami of AgRPp110&#x003b2; null and POMCp110&#x003b2; null mice, mRNA was extracted from the hypothalamus and cortex of control and mutant mice and transcribed into cDNA as previously described (<xref rid="bib7" ref-type="bibr">Choudhury et&#x000a0;al., 2005</xref>). Resulting cDNA was used as a template for PCR to amplify exons 19&#x02013;23 using primers located in exon 19 (TTGGACCTGCGGATGCTCCCCTAT) and exon 23 (CGCATCTTCACAGCACTGGCGGA). The generation of&#x000a0;a 204&#x000a0;bp&#x000a0;PCR fragment in hypothalamic samples from AgRPp110&#x003b2; null and POMCp110&#x003b2; null mice indicated successful splicing of exon 20 onto exon 23, resulting in the generation of an internally truncated p110&#x003b2; protein in these neuronal populations. All knockout and transgenic mice were studied with appropriate littermates of the three control genotypes in all studies. We did not detect any sexual dimorphism in the observed phenotypes. Any mouse that tested positive for deletion in tail tissue due to potential germline recombination of the floxed alleles was excluded from all studies. Mice were maintained on a 12 hr light/dark cycle with free access to water and standard mouse chow (4% fat, RM1, Special Diet Services) and housed in specific pathogen-free barrier facilities. Mice were handled and all in&#x000a0;vivo studies performed in accordance to the United Kingdom Animals (Scientific Procedures) Act (1986).</p></sec><sec id="sec4.2"><title>Metabolic Studies</title><p>Body weight and fat measurement, feeding, and HFD studies were performed as previously described (<xref rid="bib7 bib9" ref-type="bibr">Choudhury et&#x000a0;al., 2005; Claret et&#x000a0;al., 2007</xref>). Plasma leptin and insulin levels were determined using mouse ELISAs (Linco Inc.). MRI scanning was performed as previously described (<xref rid="bib7" ref-type="bibr">Choudhury et&#x000a0;al., 2005</xref>).</p></sec><sec id="sec4.3"><title>I.c.v. Leptin Treatment</title><p>Stainless steel cannulae were inserted into the third ventricle (midline 0 mm, 0.82 mm posterior from bregma, depth 4.8 mm from skull surface) of mice anaesthetized with isoflurane. Postsurgery, mice were singly housed and given at least a week to recover to their presurgery weight. Correct cannula placement was confirmed by demonstration of increased drinking after i.c.v. administration of angiotensin (10 ng). For i.c.v. leptin studies, food was removed from mice 4 hr prior to the onset of the dark phase, and a bolus i.c.v. injection of leptin (0.5 &#x003bc;g) or artificial cerebrospinal fluid (aCSF) was administered. Mice were returned to their home cages immediately after injection. Prior to the onset of dark phase, food was returned and food intake measured at 4 and 24 hr postinjection. All injections were done with an internal cannula projecting 0.5 mm below the tip of the cannula.</p></sec><sec id="sec4.4"><title>Quantitative RT-PCR Analysis</title><p>Quantitative RT-PCR was performed as previously described (<xref rid="bib9" ref-type="bibr">Claret et&#x000a0;al., 2007</xref>). Proprietary sequence Taqman Gene Expression assay FAM/TAMRA primers (Applied Biosystems, Foster City, CA, USA) were used: <italic>Agrp</italic> (Mm00475829_g1), <italic>Hprt</italic> (Mm00446968_m1), <italic>Npy</italic> (Mm00445771_m1), and <italic>Pomc</italic> (Mm00435874_m1).</p></sec><sec id="sec4.5"><title>Lipid Kinase Assays</title><p>PI3K activity assays on hypothalamic lysates were performed as previously described (<xref rid="bib4" ref-type="bibr">Bilancio et&#x000a0;al., 2006</xref>).</p></sec><sec id="sec4.6"><title>Electrophysiology</title><p>Hypothalamic coronal slices (350 &#x003bc;m) were cut from 6- to 18-week-old transgenic mice expressing POMCCreZ/EG or AgRPCreRosa26YFP with or without p110&#x003b1; or p110&#x003b2; mutant alleles. Slices were maintained at room temperature (22&#x000b0;C&#x02013;25&#x000b0;C) in an external solution containing (in mM) NaCl 125, KCl 2.5, NaH<sub>2</sub>PO<sub>4</sub> 1.25, NaHCO<sub>3</sub> 25, CaCl<sub>2</sub> 2, MgCl<sub>2</sub> 1, D-glucose 10, and D-mannitol 15 equilibrated with 95% O<sub>2</sub>, 5% CO<sub>2</sub> (pH 7.4). POMC and AgRP neurons were visualized in the ARC by the expression and excitation of GFP and YFP, respectively. Whole-cell current-clamp (I<sub>fast</sub>) recordings were made at &#x0223c;35&#x000b0;C using borosilicate glass pipettes (4&#x02013;8 M&#x003a9;) containing (in mM) Kgluconate 130, KCl 10, EGTA 0.5, NaCl 1, CaCl<sub>2</sub> 0.28, MgCl<sub>2</sub> 3, Na<sub>2</sub>ATP 3, GTP 0.3, phosphocreatine 14, and HEPES 10 (pH 7.2), as previously described (<xref rid="bib7 bib9 bib38" ref-type="bibr">Choudhury et&#x000a0;al., 2005; Claret et&#x000a0;al., 2007; Smith et&#x000a0;al., 2007</xref>). Following a minimum of 10 min of stable recording, hormones were applied for 2&#x02013;3 min using a broken tipped pipette (&#x0223c;3 &#x003bc;m) positioned above the recording neuron. Stock reagents were diluted (&#x02265;1000-fold) in a modified external solution with NaHCO<sub>3</sub> replaced with HEPES (10 mM, pH 7.4). Stocks of recombinant leptin (R&#x00026;D Systems), insulin (Novo-Nordisk Inc.), TGX-221 (Cayman Chemical Inc.), and wortmannin (Calbiochem Inc.) were diluted in HEPES-buffered external or internal solutions. All other reagents were purchased from Sigma-Aldrich.</p></sec><sec id="sec4.7"><title>Statistical Analysis</title><p>Data are expressed as mean &#x000b1; SEM. P values were calculated using nonparametric (Mann-Whitney U test) and parametric (unpaired and paired t tests) tests, performed as appropriate. P values &#x02264;0.05 were considered statistically significant. Statistical significance was calculated from all recordings (responsive and nonresponsive) using a Student's two-tailed paired t test or ANOVA, followed by Bonferroni's post hoc test where appropriate.</p><p>Additional experimental procedures are presented in the <xref rid="app2" ref-type="sec">Supplemental Data</xref>.</p></sec></sec><sec id="app1" sec-type="supplementary-material"><title>Supplemental Data</title><p>Supplemental Data include Supplemental Experimental Procedures, 12 figures, 3 tables, and Supplemental References and can be found with this article online at <ext-link xlink:href="http://www.cell.com/cell-metabolism/supplemental/S1550-4131(09)00296-4" ext-link-type="uri">http://www.cell.com/cell-metabolism/supplemental/S1550-4131(09)00296-4</ext-link>.</p></sec><sec id="app2" sec-type="supplementary-material"><title>Supplemental Data</title><p><supplementary-material content-type="local-data" id="mmc1"><caption><title>Document S1. Supplemental Experimental Procedures, 12 Figures, 3 Tables, and Supplemental References</title></caption><media xlink:href="mmc1.pdf" mimetype="application" mime-subtype="pdf"/></supplementary-material></p></sec></body><back><ack><title>Acknowledgments</title><p>The work was supported by grants from the Wellcome Trust (D.J.W. and M.L.J.A.), the Medical Research Council (D.J.W. and R.L.B.), and the Biotechnology and Biological Sciences Research Council (D.J.W.). B.V. was supported by Diabetes UK, the Ludwig Institute for Cancer Research, and Queen Mary University of London. J.G.-G. was supported by fellowships from the European Molecular Biology Organization (ALTF676&#x02013;2005), Foundation pour la Recherche M&#x000e9;dicale (FRMSPE20051105175), and European Union Marie Curie (MEIF-CT-2006-039676). B.V. is an advisor to Intellike, San Diego.</p></ack><ref-list><title>References</title><ref id="bib1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Barsh</surname><given-names>G.S.</given-names></name><name><surname>Schwartz</surname><given-names>M.W.</given-names></name></person-group><article-title>Genetic approaches to studying energy balance: perception and integration</article-title><source>Natl. Rev.</source><year>2002</year><volume>3</volume><fpage>589</fpage><lpage>600</lpage></citation></ref><ref id="bib2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Barsh</surname><given-names>G.S.</given-names></name><name><surname>Farooqi</surname><given-names>I.S.</given-names></name><name><surname>O'Rahilly</surname><given-names>S.</given-names></name></person-group><article-title>Genetics of body-weight regulation</article-title><source>Nature</source><year>2000</year><volume>404</volume><fpage>644</fpage><lpage>651</lpage><pub-id pub-id-type="pmid">10766251</pub-id></citation></ref><ref id="bib3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bewick</surname><given-names>G.A.</given-names></name><name><surname>Gardiner</surname><given-names>J.V.</given-names></name><name><surname>Dhillo</surname><given-names>W.S.</given-names></name><name><surname>Kent</surname><given-names>A.S.</given-names></name><name><surname>White</surname><given-names>N.E.</given-names></name><name><surname>Webster</surname><given-names>Z.</given-names></name><name><surname>Ghatei</surname><given-names>M.A.</given-names></name><name><surname>Bloom</surname><given-names>S.R.</given-names></name></person-group><article-title>Post-embryonic ablation of AgRP neurons in mice leads to a lean, hypophagic phenotype</article-title><source>FASEB J.</source><year>2005</year><volume>19</volume><fpage>1680</fpage><lpage>1682</lpage><pub-id pub-id-type="pmid">16099943</pub-id></citation></ref><ref id="bib4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bilancio</surname><given-names>A.</given-names></name><name><surname>Okkenhaug</surname><given-names>K.</given-names></name><name><surname>Camps</surname><given-names>M.</given-names></name><name><surname>Emery</surname><given-names>J.L.</given-names></name><name><surname>Ruckle</surname><given-names>T.</given-names></name><name><surname>Rommel</surname><given-names>C.</given-names></name><name><surname>Vanhaesebroeck</surname><given-names>B.</given-names></name></person-group><article-title>Key role of the p110delta isoform of PI3K in B-cell antigen and IL-4 receptor signaling: comparative analysis of genetic and pharmacologic interference with p110delta function in B cells</article-title><source>Blood</source><year>2006</year><volume>107</volume><fpage>642</fpage><lpage>650</lpage><pub-id pub-id-type="pmid">16179367</pub-id></citation></ref><ref id="bib5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chaussade</surname><given-names>C.</given-names></name><name><surname>Rewcastle</surname><given-names>G.W.</given-names></name><name><surname>Kendall</surname><given-names>J.D.</given-names></name><name><surname>Denny</surname><given-names>W.A.</given-names></name><name><surname>Cho</surname><given-names>K.</given-names></name><name><surname>Gronning</surname><given-names>L.M.</given-names></name><name><surname>Chong</surname><given-names>M.L.</given-names></name><name><surname>Anagnostou</surname><given-names>S.H.</given-names></name><name><surname>Jackson</surname><given-names>S.P.</given-names></name><name><surname>Daniele</surname><given-names>N.</given-names></name><name><surname>Shepherd</surname><given-names>P.R.</given-names></name></person-group><article-title>Evidence for functional redundancy of class IA PI3K isoforms in insulin signalling</article-title><source>Biochem. J.</source><year>2007</year><volume>404</volume><fpage>449</fpage><lpage>458</lpage><pub-id pub-id-type="pmid">17362206</pub-id></citation></ref><ref id="bib6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cheung</surname><given-names>C.C.</given-names></name><name><surname>Clifton</surname><given-names>D.K.</given-names></name><name><surname>Steiner</surname><given-names>R.A.</given-names></name></person-group><article-title>Proopiomelanocortin neurons are direct targets for leptin in the hypothalamus</article-title><source>Endocrinology</source><year>1997</year><volume>138</volume><fpage>4489</fpage><lpage>4492</lpage><pub-id pub-id-type="pmid">9322969</pub-id></citation></ref><ref id="bib7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Choudhury</surname><given-names>A.I.</given-names></name><name><surname>Heffron</surname><given-names>H.</given-names></name><name><surname>Smith</surname><given-names>M.A.</given-names></name><name><surname>Al-Qassab</surname><given-names>H.</given-names></name><name><surname>Xu</surname><given-names>A.W.</given-names></name><name><surname>Selman</surname><given-names>C.</given-names></name><name><surname>Simmgen</surname><given-names>M.</given-names></name><name><surname>Clements</surname><given-names>M.</given-names></name><name><surname>Claret</surname><given-names>M.</given-names></name><name><surname>Maccoll</surname><given-names>G.</given-names></name></person-group><article-title>The role of insulin receptor substrate 2 in hypothalamic and beta cell function</article-title><source>J. Clin. Invest.</source><year>2005</year><volume>115</volume><fpage>940</fpage><lpage>950</lpage><pub-id pub-id-type="pmid">15841180</pub-id></citation></ref><ref id="bib8"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ciraolo</surname><given-names>E.</given-names></name><name><surname>Iezzi</surname><given-names>M.</given-names></name><name><surname>Marone</surname><given-names>R.</given-names></name><name><surname>Marengo</surname><given-names>S.</given-names></name><name><surname>Curcio</surname><given-names>C.</given-names></name><name><surname>Costa</surname><given-names>C.</given-names></name><name><surname>Azzolino</surname><given-names>O.</given-names></name><name><surname>Gonella</surname><given-names>C.</given-names></name><name><surname>Rubinetto</surname><given-names>C.</given-names></name><name><surname>Wu</surname><given-names>H.</given-names></name></person-group><article-title>Phosphoinositide 3-kinase p110beta activity: key role in metabolism and mammary gland cancer but not development</article-title><source>Sci. Signal.</source><year>2008</year><volume>1</volume><fpage>ra3</fpage><pub-id pub-id-type="pmid">18780892</pub-id></citation></ref><ref id="bib9"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Claret</surname><given-names>M.</given-names></name><name><surname>Smith</surname><given-names>M.A.</given-names></name><name><surname>Batterham</surname><given-names>R.L.</given-names></name><name><surname>Selman</surname><given-names>C.</given-names></name><name><surname>Choudhury</surname><given-names>A.I.</given-names></name><name><surname>Fryer</surname><given-names>L.G.</given-names></name><name><surname>Clements</surname><given-names>M.</given-names></name><name><surname>Al-Qassab</surname><given-names>H.</given-names></name><name><surname>Heffron</surname><given-names>H.</given-names></name><name><surname>Xu</surname><given-names>A.W.</given-names></name></person-group><article-title>AMPK is essential for energy homeostasis regulation and glucose sensing by POMC and AgRP neurons</article-title><source>J. Clin. Invest.</source><year>2007</year><volume>117</volume><fpage>2325</fpage><lpage>2336</lpage><pub-id pub-id-type="pmid">17671657</pub-id></citation></ref><ref id="bib10"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cowley</surname><given-names>M.A.</given-names></name><name><surname>Smart</surname><given-names>J.L.</given-names></name><name><surname>Rubinstein</surname><given-names>M.</given-names></name><name><surname>Cerdan</surname><given-names>M.G.</given-names></name><name><surname>Diano</surname><given-names>S.</given-names></name><name><surname>Horvath</surname><given-names>T.L.</given-names></name><name><surname>Cone</surname><given-names>R.D.</given-names></name><name><surname>Low</surname><given-names>M.J.</given-names></name></person-group><article-title>Leptin activates anorexigenic POMC neurons through a neural network in the arcuate nucleus</article-title><source>Nature</source><year>2001</year><volume>411</volume><fpage>480</fpage><lpage>484</lpage><pub-id pub-id-type="pmid">11373681</pub-id></citation></ref><ref id="bib11"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Elias</surname><given-names>C.F.</given-names></name><name><surname>Aschkenasi</surname><given-names>C.</given-names></name><name><surname>Lee</surname><given-names>C.</given-names></name><name><surname>Kelly</surname><given-names>J.</given-names></name><name><surname>Ahima</surname><given-names>R.S.</given-names></name><name><surname>Bjorbaek</surname><given-names>C.</given-names></name><name><surname>Flier</surname><given-names>J.S.</given-names></name><name><surname>Saper</surname><given-names>C.B.</given-names></name><name><surname>Elmquist</surname><given-names>J.K.</given-names></name></person-group><article-title>Leptin differentially regulates NPY and POMC neurons projecting to the lateral hypothalamic area</article-title><source>Neuron</source><year>1999</year><volume>23</volume><fpage>775</fpage><lpage>786</lpage><pub-id pub-id-type="pmid">10482243</pub-id></citation></ref><ref id="bib12"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Graupera</surname><given-names>M.</given-names></name><name><surname>Guillermet-Guibert</surname><given-names>J.</given-names></name><name><surname>Foukas</surname><given-names>L.C.</given-names></name><name><surname>Phng</surname><given-names>L.K.</given-names></name><name><surname>Cain</surname><given-names>R.J.</given-names></name><name><surname>Salpekar</surname><given-names>A.</given-names></name><name><surname>Pearce</surname><given-names>W.</given-names></name><name><surname>Meek</surname><given-names>S.</given-names></name><name><surname>Millan</surname><given-names>J.</given-names></name><name><surname>Cutillas</surname><given-names>P.R.</given-names></name></person-group><article-title>Angiogenesis selectively requires the p110alpha isoform of PI3K to control endothelial cell migration</article-title><source>Nature</source><year>2008</year><volume>453</volume><fpage>662</fpage><lpage>666</lpage><pub-id pub-id-type="pmid">18449193</pub-id></citation></ref><ref id="bib13"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gropp</surname><given-names>E.</given-names></name><name><surname>Shanabrough</surname><given-names>M.</given-names></name><name><surname>Borok</surname><given-names>E.</given-names></name><name><surname>Xu</surname><given-names>A.W.</given-names></name><name><surname>Janoschek</surname><given-names>R.</given-names></name><name><surname>Buch</surname><given-names>T.</given-names></name><name><surname>Plum</surname><given-names>L.</given-names></name><name><surname>Balthasar</surname><given-names>N.</given-names></name><name><surname>Hampel</surname><given-names>B.</given-names></name><name><surname>Waisman</surname><given-names>A.</given-names></name></person-group><article-title>Agouti-related peptide-expressing neurons are mandatory for feeding</article-title><source>Nat. Neurosci.</source><year>2005</year><volume>8</volume><fpage>1289</fpage><lpage>1291</lpage><pub-id pub-id-type="pmid">16158063</pub-id></citation></ref><ref id="bib14"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Guillermet-Guibert</surname><given-names>J.</given-names></name><name><surname>Bjorklof</surname><given-names>K.</given-names></name><name><surname>Salpekar</surname><given-names>A.</given-names></name><name><surname>Gonella</surname><given-names>C.</given-names></name><name><surname>Ramadani</surname><given-names>F.</given-names></name><name><surname>Bilancio</surname><given-names>A.</given-names></name><name><surname>Meek</surname><given-names>S.</given-names></name><name><surname>Smith</surname><given-names>A.J.</given-names></name><name><surname>Okkenhaug</surname><given-names>K.</given-names></name><name><surname>Vanhaesebroeck</surname><given-names>B.</given-names></name></person-group><article-title>The p110beta isoform of phosphoinositide 3-kinase signals downstream of G protein-coupled receptors and is functionally redundant with p110gamma</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2008</year><volume>105</volume><fpage>8292</fpage><lpage>8297</lpage><pub-id pub-id-type="pmid">18544649</pub-id></citation></ref><ref id="bib15"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hill</surname><given-names>J.W.</given-names></name><name><surname>Williams</surname><given-names>K.W.</given-names></name><name><surname>Ye</surname><given-names>C.</given-names></name><name><surname>Luo</surname><given-names>J.</given-names></name><name><surname>Balthasar</surname><given-names>N.</given-names></name><name><surname>Coppari</surname><given-names>R.</given-names></name><name><surname>Cowley</surname><given-names>M.A.</given-names></name><name><surname>Cantley</surname><given-names>L.C.</given-names></name><name><surname>Lowell</surname><given-names>B.B.</given-names></name><name><surname>Elmquist</surname><given-names>J.K.</given-names></name></person-group><article-title>Acute effects of leptin require PI3K signaling in hypothalamic proopiomelanocortin neurons in mice</article-title><source>J. Clin. Invest.</source><year>2008</year><volume>118</volume><fpage>1796</fpage><lpage>1805</lpage><pub-id pub-id-type="pmid">18382766</pub-id></citation></ref><ref id="bib16"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Huo</surname><given-names>L.</given-names></name><name><surname>Gamber</surname><given-names>K.</given-names></name><name><surname>Greeley</surname><given-names>S.</given-names></name><name><surname>Silva</surname><given-names>J.</given-names></name><name><surname>Huntoon</surname><given-names>N.</given-names></name><name><surname>Leng</surname><given-names>X.H.</given-names></name><name><surname>Bjorbaek</surname><given-names>C.</given-names></name></person-group><article-title>Leptin-dependent control of glucose balance and locomotor activity by POMC neurons</article-title><source>Cell Metab.</source><year>2009</year><volume>9</volume><fpage>537</fpage><lpage>547</lpage><pub-id pub-id-type="pmid">19490908</pub-id></citation></ref><ref id="bib17"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jackson</surname><given-names>S.P.</given-names></name><name><surname>Schoenwaelder</surname><given-names>S.M.</given-names></name><name><surname>Goncalves</surname><given-names>I.</given-names></name><name><surname>Nesbitt</surname><given-names>W.S.</given-names></name><name><surname>Yap</surname><given-names>C.L.</given-names></name><name><surname>Wright</surname><given-names>C.E.</given-names></name><name><surname>Kenche</surname><given-names>V.</given-names></name><name><surname>Anderson</surname><given-names>K.E.</given-names></name><name><surname>Dopheide</surname><given-names>S.M.</given-names></name><name><surname>Yuan</surname><given-names>Y.</given-names></name></person-group><article-title>PI 3-kinase p110beta: a new target for antithrombotic therapy</article-title><source>Nat. Med.</source><year>2005</year><volume>11</volume><fpage>507</fpage><lpage>514</lpage><pub-id pub-id-type="pmid">15834429</pub-id></citation></ref><ref id="bib18"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jia</surname><given-names>S.</given-names></name><name><surname>Liu</surname><given-names>Z.</given-names></name><name><surname>Zhang</surname><given-names>S.</given-names></name><name><surname>Liu</surname><given-names>P.</given-names></name><name><surname>Zhang</surname><given-names>L.</given-names></name><name><surname>Lee</surname><given-names>S.H.</given-names></name><name><surname>Zhang</surname><given-names>J.</given-names></name><name><surname>Signoretti</surname><given-names>S.</given-names></name><name><surname>Loda</surname><given-names>M.</given-names></name><name><surname>Roberts</surname><given-names>T.M.</given-names></name><name><surname>Zhao</surname><given-names>J.J.</given-names></name></person-group><article-title>Essential roles of PI(3)K-p110beta in cell growth, metabolism and tumorigenesis</article-title><source>Nature</source><year>2008</year><volume>454</volume><fpage>776</fpage><lpage>779</lpage><pub-id pub-id-type="pmid">18594509</pub-id></citation></ref><ref id="bib19"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>M.S.</given-names></name><name><surname>Pak</surname><given-names>Y.K.</given-names></name><name><surname>Jang</surname><given-names>P.G.</given-names></name><name><surname>Namkoong</surname><given-names>C.</given-names></name><name><surname>Choi</surname><given-names>Y.S.</given-names></name><name><surname>Won</surname><given-names>J.C.</given-names></name><name><surname>Kim</surname><given-names>K.S.</given-names></name><name><surname>Kim</surname><given-names>S.W.</given-names></name><name><surname>Kim</surname><given-names>H.S.</given-names></name><name><surname>Park</surname><given-names>J.Y.</given-names></name></person-group><article-title>Role of hypothalamic Foxo1 in the regulation of food intake and energy homeostasis</article-title><source>Nat. Neurosci.</source><year>2006</year><volume>9</volume><fpage>901</fpage><lpage>906</lpage><pub-id pub-id-type="pmid">16783365</pub-id></citation></ref><ref id="bib20"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kitamura</surname><given-names>T.</given-names></name><name><surname>Feng</surname><given-names>Y.</given-names></name><name><surname>Kitamura</surname><given-names>Y.I.</given-names></name><name><surname>Chua</surname><given-names>S.C.</given-names></name><name><surname>Xu</surname><given-names>A.W.</given-names></name><name><surname>Barsh</surname><given-names>G.S.</given-names></name><name><surname>Rossetti</surname><given-names>L.</given-names></name><name><surname>Accili</surname><given-names>D.</given-names></name></person-group><article-title>Forkhead protein FoxO1 mediates Agrp-dependent effects of leptin on food intake</article-title><source>Nat. Med.</source><year>2006</year><volume>12</volume><fpage>534</fpage><lpage>540</lpage><pub-id pub-id-type="pmid">16604086</pub-id></citation></ref><ref id="bib21"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Knight</surname><given-names>Z.A.</given-names></name><name><surname>Gonzalez</surname><given-names>B.</given-names></name><name><surname>Feldman</surname><given-names>M.E.</given-names></name><name><surname>Zunder</surname><given-names>E.R.</given-names></name><name><surname>Goldenberg</surname><given-names>D.D.</given-names></name><name><surname>Williams</surname><given-names>O.</given-names></name><name><surname>Loewith</surname><given-names>R.</given-names></name><name><surname>Stokoe</surname><given-names>D.</given-names></name><name><surname>Balla</surname><given-names>A.</given-names></name><name><surname>Toth</surname><given-names>B.</given-names></name></person-group><article-title>A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling</article-title><source>Cell</source><year>2006</year><volume>125</volume><fpage>733</fpage><lpage>747</lpage><pub-id pub-id-type="pmid">16647110</pub-id></citation></ref><ref id="bib22"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Konner</surname><given-names>A.C.</given-names></name><name><surname>Janoschek</surname><given-names>R.</given-names></name><name><surname>Plum</surname><given-names>L.</given-names></name><name><surname>Jordan</surname><given-names>S.D.</given-names></name><name><surname>Rother</surname><given-names>E.</given-names></name><name><surname>Ma</surname><given-names>X.</given-names></name><name><surname>Xu</surname><given-names>C.</given-names></name><name><surname>Enriori</surname><given-names>P.</given-names></name><name><surname>Hampel</surname><given-names>B.</given-names></name><name><surname>Barsh</surname><given-names>G.S.</given-names></name></person-group><article-title>Insulin action in AgRP-expressing neurons is required for suppression of hepatic glucose production</article-title><source>Cell Metab.</source><year>2007</year><volume>5</volume><fpage>438</fpage><lpage>449</lpage><pub-id pub-id-type="pmid">17550779</pub-id></citation></ref><ref id="bib23"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Luquet</surname><given-names>S.</given-names></name><name><surname>Perez</surname><given-names>F.A.</given-names></name><name><surname>Hnasko</surname><given-names>T.S.</given-names></name><name><surname>Palmiter</surname><given-names>R.D.</given-names></name></person-group><article-title>NPY/AgRP neurons are essential for feeding in adult mice but can be ablated in neonates</article-title><source>Science (New York)</source><year>2005</year><volume>310</volume><fpage>683</fpage><lpage>685</lpage></citation></ref><ref id="bib24"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Marone</surname><given-names>R.</given-names></name><name><surname>Cmiljanovic</surname><given-names>V.</given-names></name><name><surname>Giese</surname><given-names>B.</given-names></name><name><surname>Wymann</surname><given-names>M.P.</given-names></name></person-group><article-title>Targeting phosphoinositide 3-kinase: moving towards therapy</article-title><source>Biochim. Biophys. Acta</source><year>2008</year><volume>1784</volume><fpage>159</fpage><lpage>185</lpage><pub-id pub-id-type="pmid">17997386</pub-id></citation></ref><ref id="bib25"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Morton</surname><given-names>G.J.</given-names></name><name><surname>Gelling</surname><given-names>R.W.</given-names></name><name><surname>Niswender</surname><given-names>K.D.</given-names></name><name><surname>Morrison</surname><given-names>C.D.</given-names></name><name><surname>Rhodes</surname><given-names>C.J.</given-names></name><name><surname>Schwartz</surname><given-names>M.W.</given-names></name></person-group><article-title>Leptin regulates insulin sensitivity via phosphatidylinositol-3-OH kinase signaling in mediobasal hypothalamic neurons</article-title><source>Cell Metab.</source><year>2005</year><volume>2</volume><fpage>411</fpage><lpage>420</lpage><pub-id pub-id-type="pmid">16330326</pub-id></citation></ref><ref id="bib26"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Morton</surname><given-names>G.J.</given-names></name><name><surname>Cummings</surname><given-names>D.E.</given-names></name><name><surname>Baskin</surname><given-names>D.G.</given-names></name><name><surname>Barsh</surname><given-names>G.S.</given-names></name><name><surname>Schwartz</surname><given-names>M.W.</given-names></name></person-group><article-title>Central nervous system control of food intake and body weight</article-title><source>Nature</source><year>2006</year><volume>443</volume><fpage>289</fpage><lpage>295</lpage><pub-id pub-id-type="pmid">16988703</pub-id></citation></ref><ref id="bib27"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ning</surname><given-names>K.</given-names></name><name><surname>Miller</surname><given-names>L.C.</given-names></name><name><surname>Laidlaw</surname><given-names>H.A.</given-names></name><name><surname>Burgess</surname><given-names>L.A.</given-names></name><name><surname>Perera</surname><given-names>N.M.</given-names></name><name><surname>Downes</surname><given-names>C.P.</given-names></name><name><surname>Leslie</surname><given-names>N.R.</given-names></name><name><surname>Ashford</surname><given-names>M.L.</given-names></name></person-group><article-title>A novel leptin signalling pathway via PTEN inhibition in hypothalamic cell lines and pancreatic beta-cells</article-title><source>EMBO J.</source><year>2006</year><volume>25</volume><fpage>2377</fpage><lpage>2387</lpage><pub-id pub-id-type="pmid">16675953</pub-id></citation></ref><ref id="bib28"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Niswender</surname><given-names>K.D.</given-names></name><name><surname>Morton</surname><given-names>G.J.</given-names></name><name><surname>Stearns</surname><given-names>W.H.</given-names></name><name><surname>Rhodes</surname><given-names>C.J.</given-names></name><name><surname>Myers</surname><given-names>M.G.</given-names></name><name><surname>Schwartz</surname><given-names>M.W.</given-names></name></person-group><article-title>Intracellular signalling. Key enzyme in leptin-induced anorexia</article-title><source>Nature</source><year>2001</year><volume>413</volume><fpage>794</fpage><lpage>795</lpage><pub-id pub-id-type="pmid">11677594</pub-id></citation></ref><ref id="bib29"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Niswender</surname><given-names>K.D.</given-names></name><name><surname>Morrison</surname><given-names>C.D.</given-names></name><name><surname>Clegg</surname><given-names>D.J.</given-names></name><name><surname>Olson</surname><given-names>R.</given-names></name><name><surname>Baskin</surname><given-names>D.G.</given-names></name><name><surname>Myers</surname><given-names>M.G.</given-names></name><name><surname>Seeley</surname><given-names>R.J.</given-names></name><name><surname>Schwartz</surname><given-names>M.W.</given-names></name></person-group><article-title>Insulin activation of phosphatidylinositol 3-kinase in the hypothalamic arcuate nucleus: a key mediator of insulin-induced anorexia</article-title><source>Diabetes</source><year>2003</year><volume>52</volume><fpage>227</fpage><lpage>231</lpage><pub-id pub-id-type="pmid">12540590</pub-id></citation></ref><ref id="bib30"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Novak</surname><given-names>A.</given-names></name><name><surname>Guo</surname><given-names>C.</given-names></name><name><surname>Yang</surname><given-names>W.</given-names></name><name><surname>Nagy</surname><given-names>A.</given-names></name><name><surname>Lobe</surname><given-names>C.G.</given-names></name></person-group><article-title>Z/EG, a double reporter mouse line that expresses enhanced green fluorescent protein upon Cre-mediated excision</article-title><source>Genesis</source><year>2000</year><volume>28</volume><fpage>147</fpage><lpage>155</lpage><pub-id pub-id-type="pmid">11105057</pub-id></citation></ref><ref id="bib31"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Okkenhaug</surname><given-names>K.</given-names></name><name><surname>Vanhaesebroeck</surname><given-names>B.</given-names></name></person-group><article-title>New responsibilities for the PI3K regulatory subunit p85 alpha</article-title><source>Sci. STKE</source><year>2001</year><volume>2001</volume><fpage>PE1</fpage><pub-id pub-id-type="pmid">11752634</pub-id></citation></ref><ref id="bib32"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Parton</surname><given-names>L.E.</given-names></name><name><surname>Ye</surname><given-names>C.P.</given-names></name><name><surname>Coppari</surname><given-names>R.</given-names></name><name><surname>Enriori</surname><given-names>P.J.</given-names></name><name><surname>Choi</surname><given-names>B.</given-names></name><name><surname>Zhang</surname><given-names>C.Y.</given-names></name><name><surname>Xu</surname><given-names>C.</given-names></name><name><surname>Vianna</surname><given-names>C.R.</given-names></name><name><surname>Balthasar</surname><given-names>N.</given-names></name><name><surname>Lee</surname><given-names>C.E.</given-names></name></person-group><article-title>Glucose sensing by POMC neurons regulates glucose homeostasis and is impaired in obesity</article-title><source>Nature</source><year>2007</year><volume>449</volume><fpage>228</fpage><lpage>232</lpage><pub-id pub-id-type="pmid">17728716</pub-id></citation></ref><ref id="bib33"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Patel</surname><given-names>H.R.</given-names></name><name><surname>Qi</surname><given-names>Y.</given-names></name><name><surname>Hawkins</surname><given-names>E.J.</given-names></name><name><surname>Hileman</surname><given-names>S.M.</given-names></name><name><surname>Elmquist</surname><given-names>J.K.</given-names></name><name><surname>Imai</surname><given-names>Y.</given-names></name><name><surname>Ahima</surname><given-names>R.S.</given-names></name></person-group><article-title>Neuropeptide Y deficiency attenuates responses to fasting and high-fat diet in obesity-prone mice</article-title><source>Diabetes</source><year>2006</year><volume>55</volume><fpage>3091</fpage><lpage>3098</lpage><pub-id pub-id-type="pmid">17065347</pub-id></citation></ref><ref id="bib34"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Plum</surname><given-names>L.</given-names></name><name><surname>Ma</surname><given-names>X.</given-names></name><name><surname>Hampel</surname><given-names>B.</given-names></name><name><surname>Balthasar</surname><given-names>N.</given-names></name><name><surname>Coppari</surname><given-names>R.</given-names></name><name><surname>Munzberg</surname><given-names>H.</given-names></name><name><surname>Shanabrough</surname><given-names>M.</given-names></name><name><surname>Burdakov</surname><given-names>D.</given-names></name><name><surname>Rother</surname><given-names>E.</given-names></name><name><surname>Janoschek</surname><given-names>R.</given-names></name></person-group><article-title>Enhanced PIP3 signaling in POMC neurons causes KATP channel activation and leads to diet-sensitive obesity</article-title><source>J. Clin. Invest.</source><year>2006</year><volume>116</volume><fpage>1886</fpage><lpage>1901</lpage><pub-id pub-id-type="pmid">16794735</pub-id></citation></ref><ref id="bib35"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Plum</surname><given-names>L.</given-names></name><name><surname>Rother</surname><given-names>E.</given-names></name><name><surname>Munzberg</surname><given-names>H.</given-names></name><name><surname>Wunderlich</surname><given-names>F.T.</given-names></name><name><surname>Morgan</surname><given-names>D.A.</given-names></name><name><surname>Hampel</surname><given-names>B.</given-names></name><name><surname>Shanabrough</surname><given-names>M.</given-names></name><name><surname>Janoschek</surname><given-names>R.</given-names></name><name><surname>Konner</surname><given-names>A.C.</given-names></name><name><surname>Alber</surname><given-names>J.</given-names></name></person-group><article-title>Enhanced leptin-stimulated Pi3k activation in the CNS promotes white adipose tissue transdifferentiation</article-title><source>Cell Metab.</source><year>2007</year><volume>6</volume><fpage>431</fpage><lpage>445</lpage><pub-id pub-id-type="pmid">18054313</pub-id></citation></ref><ref id="bib36"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shaywitz</surname><given-names>A.J.</given-names></name><name><surname>Courtney</surname><given-names>K.D.</given-names></name><name><surname>Patnaik</surname><given-names>A.</given-names></name><name><surname>Cantley</surname><given-names>L.C.</given-names></name></person-group><article-title>PI3K enters beta-testing</article-title><source>Cell Metab.</source><year>2008</year><volume>8</volume><fpage>179</fpage><lpage>181</lpage><pub-id pub-id-type="pmid">18762017</pub-id></citation></ref><ref id="bib37"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shepherd</surname><given-names>P.R.</given-names></name><name><surname>Withers</surname><given-names>D.J.</given-names></name><name><surname>Siddle</surname><given-names>K.</given-names></name></person-group><article-title>Phosphoinositide 3-kinase: the key switch mechanism in insulin signalling</article-title><source>Biochem. J.</source><year>1998</year><volume>333</volume><fpage>471</fpage><lpage>490</lpage><pub-id pub-id-type="pmid">9677303</pub-id></citation></ref><ref id="bib38"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>M.A.</given-names></name><name><surname>Hisadome</surname><given-names>K.</given-names></name><name><surname>Al-Qassab</surname><given-names>H.</given-names></name><name><surname>Heffron</surname><given-names>H.</given-names></name><name><surname>Withers</surname><given-names>D.J.</given-names></name><name><surname>Ashford</surname><given-names>M.L.</given-names></name></person-group><article-title>Melanocortins and agouti-related protein modulate the excitability of two arcuate nucleus neuron populations by alteration of resting potassium conductances</article-title><source>J. Physiol.</source><year>2007</year><volume>578</volume><fpage>425</fpage><lpage>438</lpage><pub-id pub-id-type="pmid">17068101</pub-id></citation></ref><ref id="bib39"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Srinivas</surname><given-names>S.</given-names></name><name><surname>Watanabe</surname><given-names>T.</given-names></name><name><surname>Lin</surname><given-names>C.S.</given-names></name><name><surname>William</surname><given-names>C.M.</given-names></name><name><surname>Tanabe</surname><given-names>Y.</given-names></name><name><surname>Jessell</surname><given-names>T.M.</given-names></name><name><surname>Costantini</surname><given-names>F.</given-names></name></person-group><article-title>Cre reporter strains produced by targeted insertion of EYFP and ECFP into the ROSA26 locus</article-title><source>BMC Dev. Biol.</source><year>2001</year><volume>1</volume><fpage>4</fpage><pub-id pub-id-type="pmid">11299042</pub-id></citation></ref><ref id="bib40"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ueki</surname><given-names>K.</given-names></name><name><surname>Yballe</surname><given-names>C.M.</given-names></name><name><surname>Brachmann</surname><given-names>S.M.</given-names></name><name><surname>Vicent</surname><given-names>D.</given-names></name><name><surname>Watt</surname><given-names>J.M.</given-names></name><name><surname>Kahn</surname><given-names>C.R.</given-names></name><name><surname>Cantley</surname><given-names>L.C.</given-names></name></person-group><article-title>Increased insulin sensitivity in mice lacking p85beta subunit of phosphoinositide 3-kinase</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2002</year><volume>99</volume><fpage>419</fpage><lpage>424</lpage><pub-id pub-id-type="pmid">11752399</pub-id></citation></ref><ref id="bib41"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>van den Top</surname><given-names>M.</given-names></name><name><surname>Lee</surname><given-names>K.</given-names></name><name><surname>Whyment</surname><given-names>A.D.</given-names></name><name><surname>Blanks</surname><given-names>A.M.</given-names></name><name><surname>Spanswick</surname><given-names>D.</given-names></name></person-group><article-title>Orexigen-sensitive NPY/AgRP pacemaker neurons in the hypothalamic arcuate nucleus</article-title><source>Nat. Neurosci.</source><year>2004</year><volume>7</volume><fpage>493</fpage><lpage>494</lpage><pub-id pub-id-type="pmid">15097991</pub-id></citation></ref><ref id="bib42"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Vanhaesebroeck</surname><given-names>B.</given-names></name><name><surname>Ali</surname><given-names>K.</given-names></name><name><surname>Bilancio</surname><given-names>A.</given-names></name><name><surname>Geering</surname><given-names>B.</given-names></name><name><surname>Foukas</surname><given-names>L.C.</given-names></name></person-group><article-title>Signalling by PI3K isoforms: insights from gene-targeted mice</article-title><source>Trends Biochem. Sci.</source><year>2005</year><volume>30</volume><fpage>194</fpage><lpage>204</lpage><pub-id pub-id-type="pmid">15817396</pub-id></citation></ref><ref id="bib43"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Woods</surname><given-names>S.C.</given-names></name><name><surname>Seeley</surname><given-names>R.J.</given-names></name><name><surname>Cota</surname><given-names>D.</given-names></name></person-group><article-title>Regulation of food intake through hypothalamic signaling networks involving mTOR</article-title><source>Annu. Rev. Nutr.</source><year>2008</year><volume>28</volume><fpage>295</fpage><lpage>311</lpage><pub-id pub-id-type="pmid">18429698</pub-id></citation></ref><ref id="bib44"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wortley</surname><given-names>K.E.</given-names></name><name><surname>Anderson</surname><given-names>K.D.</given-names></name><name><surname>Yasenchak</surname><given-names>J.</given-names></name><name><surname>Murphy</surname><given-names>A.</given-names></name><name><surname>Valenzuela</surname><given-names>D.</given-names></name><name><surname>Diano</surname><given-names>S.</given-names></name><name><surname>Yancopoulos</surname><given-names>G.D.</given-names></name><name><surname>Wiegand</surname><given-names>S.J.</given-names></name><name><surname>Sleeman</surname><given-names>M.W.</given-names></name></person-group><article-title>Agouti-related protein-deficient mice display an age-related lean phenotype</article-title><source>Cell Metab.</source><year>2005</year><volume>2</volume><fpage>421</fpage><lpage>427</lpage><pub-id pub-id-type="pmid">16330327</pub-id></citation></ref><ref id="bib45"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wymann</surname><given-names>M.P.</given-names></name><name><surname>Zvelebil</surname><given-names>M.</given-names></name><name><surname>Laffargue</surname><given-names>M.</given-names></name></person-group><article-title>Phosphoinositide 3-kinase signalling&#x02014;which way to target?</article-title><source>Trends Pharmacol. Sci.</source><year>2003</year><volume>24</volume><fpage>366</fpage><lpage>376</lpage><pub-id pub-id-type="pmid">12871670</pub-id></citation></ref><ref id="bib46"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>A.W.</given-names></name><name><surname>Kaelin</surname><given-names>C.B.</given-names></name><name><surname>Morton</surname><given-names>G.J.</given-names></name><name><surname>Ogimoto</surname><given-names>K.</given-names></name><name><surname>Stanhope</surname><given-names>K.</given-names></name><name><surname>Graham</surname><given-names>J.</given-names></name><name><surname>Baskin</surname><given-names>D.G.</given-names></name><name><surname>Havel</surname><given-names>P.</given-names></name><name><surname>Schwartz</surname><given-names>M.W.</given-names></name><name><surname>Barsh</surname><given-names>G.S.</given-names></name></person-group><article-title>Effects of hypothalamic neurodegeneration on energy balance</article-title><source>PLoS Biol.</source><year>2005</year><volume>3</volume><fpage>e415</fpage><pub-id pub-id-type="pmid">16296893</pub-id></citation></ref><ref id="bib47"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>A.W.</given-names></name><name><surname>Kaelin</surname><given-names>C.B.</given-names></name><name><surname>Takeda</surname><given-names>K.</given-names></name><name><surname>Akira</surname><given-names>S.</given-names></name><name><surname>Schwartz</surname><given-names>M.W.</given-names></name><name><surname>Barsh</surname><given-names>G.S.</given-names></name></person-group><article-title>PI3K integrates the action of insulin and leptin on hypothalamic neurons</article-title><source>J. Clin. Invest.</source><year>2005</year><volume>115</volume><fpage>951</fpage><lpage>958</lpage><pub-id pub-id-type="pmid">15761497</pub-id></citation></ref></ref-list></back><floats-wrap><fig id="fig1"><label>Figure&#x000a0;1</label><caption><p>Genetic Inactivation of p110&#x003b1; and p110&#x003b2; in Hypothalami of POMCp110 Null and AgRPp110 Null Mice</p><p>Recombination of p110&#x003b1; (A) or p110&#x003b2; (B) alleles in the hypothalamus (H), but not the cerebral cortex (C), of POMCp110null and AgRPp110 null mice. Unaltered expression of p85 and reduction of p110&#x003b1; activity (C) or p110&#x003b2; activity (D) in hypothalamic lysates from POMCp110 null and AgRPp110 null mice, n &#x0003d; 3. All values are mean &#x000b1; SEM, <sup>&#x02217;</sup>p&#x000a0;&#x0003c;&#x000a0;0.05.</p></caption><graphic xlink:href="gr1"/></fig><fig id="fig2"><label>Figure&#x000a0;2</label><caption><p>Energy Homeostasis Phenotypes in POMCp110&#x003b1; Null and POMCp110&#x003b2; Null Mice</p><p>Body weight curves of male POMCp110&#x003b2; null (A) and POMCp110&#x003b1; null (B) mice on chow diet, n &#x0003d; 30 per genotype. (C) Fat pad mass in 40-week-old POMCp110&#x003b1; null and POMCp110&#x003b2; null mice, n &#x0003d; 10. (D) Fasting plasma leptin levels in control, POMCp110&#x003b1; null, and POMCp110&#x003b2; null mice, n&#x000a0;&#x0003d; 8. (E) Twenty-four hour food intake under freely feeding conditions in 12-week-old male control, POMCp110&#x003b1; null and POMCp110&#x003b2; null mice, n&#x000a0;&#x0003d;&#x000a0;10&#x02013;14. Food intake after overnight fast in 16-week-old male POMCp110&#x003b1; null (F) and POMCp110&#x003b2; null (G) mice, n &#x0003d; 10&#x02013;14. Body weight (H), percentage fat mass (I), and fasting plasma leptin levels (J) of POMCp110&#x003b1; null and POMCp110&#x003b2; null mice following 18 week exposure to HFD, n &#x0003d; 10&#x02013;15. All values are mean &#x000b1; SEM, <sup>&#x02217;</sup>p &#x0003c; 0.05.</p></caption><graphic xlink:href="gr2"/></fig><fig id="fig3"><label>Figure&#x000a0;3</label><caption><p>Energy Homeostasis Phenotypes in AgRPp110&#x003b1; Null and AgRPp110&#x003b2; Null Mice</p><p>Body weight curves of male AgRPp110&#x003b2; null (A) and AgRPp110&#x003b1; null (B) mice on chow diet, n &#x0003d; 30 per genotype. (C) Percentage fat pad mass in 40-week-old AgRPp110&#x003b1; null and AgRPp110&#x003b2; null mice, n &#x0003d; 10. (D) Fasting plasma leptin levels in AgRPp110&#x003b1; null and AgRPp110&#x003b2; null mice, n&#x000a0;&#x0003d; 8. (E) Twenty-four hour food intake under freely&#x000a0;feeding conditions in 12-week-old male AgRPp110&#x003b1; null and AgRPp110&#x003b2; null mice, n &#x0003d; 10&#x02013;14. Food intake after overnight fast in 16-week-old male AgRPp110&#x003b1; null (F) and AgRPp110&#x003b2; null (G) mice, n &#x0003d; 10&#x02013;12. Body weight (H), percentage fat mass (I), and fasting plasma leptin levels (J) of AgRPp110&#x003b1; null and AgRPp110&#x003b2; null mice following 18 week exposure to HFD, n &#x0003d; 10&#x02013;15. All values are mean &#x000b1; SEM, <sup>&#x02217;</sup>p&#x000a0;&#x0003c;&#x000a0;0.05, <sup>&#x02217;&#x02217;</sup>p &#x0003c; 0.01, <sup>&#x02217;&#x02217;&#x02217;</sup>p &#x0003c; 0.001.</p></caption><graphic xlink:href="gr3"/></fig><fig id="fig4"><label>Figure&#x000a0;4</label><caption><p>Response to Centrally Administered Leptin and Hypothalamic Neuropeptide Expression of POMCp110&#x003b2; Null and AgRPp110&#x003b2; Null Mice</p><p>Suppression of food intake in POMCp110&#x003b2; null (A) and AgRPp110&#x003b2; null (B) mice following i.c.v. injection of leptin (0.5 &#x003bc;g), n &#x0003d; 8. Pomc, Agrp, and Npy mRNA expression in hypothalami of POMCp110&#x003b2; null (C) and AgRPp110&#x003b2; null (D) mice. All values are mean &#x000b1; SEM, <sup>&#x02217;</sup>p &#x0003c; 0.05, <sup>&#x02217;&#x02217;&#x02217;</sup>p &#x0003c; 0.001.</p></caption><graphic xlink:href="gr4"/></fig><fig id="fig5"><label>Figure&#x000a0;5</label><caption><p>PI3K Activity Underlies Leptin and Insulin Modulation of POMC Neuronal Excitability</p><p>Whole-cell recordings were made from control (A,&#x000a0;D, E, H, I, and J), p110&#x003b1; null (B and F), and p110&#x003b2; null (C and G) POMC neurons. Continuous current-clamp traces are shown in upper traces and expanded sections in lower traces, respectively. A minority population of control (A) and p110&#x003b1; null (B) POMC neurons were depolarized by leptin (50 nM for 2 min, as indicated by the arrows), which was associated with an increase in spike firing frequency (upward deflections). Leptin hyperpolarized a minority population of p110&#x003b2; null (C) but had no effect on the majority of p110&#x003b2;-inhibited (1 &#x003bc;M TGX-221) (D) POMC neurons. (E) Insulin (50 nM for 2 min, where indicated) hyperpolarized the majority of POMC neurons, which was reversed by the subsequent application of 200 &#x003bc;M tolbutamide. Note that there was a small reduction in input resistance following insulin application, as denoted by the reduced amplitude of the periodic downward deflections shown in the continuous trace. Genetic inactivation of p110&#x003b1; (F) or p110&#x003b2; (G) prevented insulin modulation of POMC neuron excitability. Pharmacological inhibition of p110&#x003b2; (1 &#x003bc;M TGX-221) (H) or&#x000a0;a general PI3K inhibitor (100 nM PI-103) (I) prevented insulin modulation of POMC neuronal&#x000a0;excitability. (J) Representative continuous current-clamp trace before and after sequential leptin and insulin (50 nM for 2 min) application as indicated by the arrows. Expanded sections are shown underneath at time points indicated by the corresponding letters in italics. Note that leptin-induced depolarization was reversed by subsequent insulin application, although a subsequent leptin administration had no effect on membrane potential.</p></caption><graphic xlink:href="gr5"/></fig><fig id="fig6"><label>Figure&#x000a0;6</label><caption><p>Insulin-Induced Depolarization of&#x000a0;AgRP Neurons Is Dependent on p110&#x003b1; and p110&#x003b2; Expression</p><p>Leptin (50 nM) does not modulate the excitability of control (A) and p110&#x003b1; (B) or p110&#x003b2; (C) null AgRP neurons. (D) A minority population of AgRP neurons were depolarized by insulin (50 nM), and this was associated with an increase in spike firing frequency. A proportion of p110&#x003b1; (E) and p110&#x003b2; (F) null or PI3K-inhibited (100 nM wortmannin; G) AgRP neurons were hyperpolarized by insulin, and this effect was reversibly occluded by 200&#x000a0;&#x003bc;M tolbutamide.</p></caption><graphic xlink:href="gr6"/></fig><table-wrap position="float" id="tbl1"><label>Table 1</label><caption><p>Effects of Leptin and Insulin on POMC and AgRP Neuron Excitability</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th colspan="2">Total<hr/></th><th colspan="2">Responsive<hr/></th></tr><tr><th/><th>&#x00394;Vm (mV)<hr/></th><th>&#x00394; Spike (Hz)<hr/></th><th>&#x00394;Vm (mV)<hr/></th><th>&#x00394; Spike (Hz)<hr/></th></tr><tr><th colspan="5">&#x0002b;Leptin</th></tr></thead><tbody><tr><td>POMC</td><td align="char">&#x0002b;1.3 &#x000b1; 0.6<sup>&#x02217;</sup> (21)</td><td align="char">&#x0002b;0.5 &#x000b1; 0.3 (21)</td><td align="char">&#x0002b;4.5 &#x000b1; 1.3 (6/21)</td><td align="char">&#x0002b;1.6 &#x000b1; 0.4 (6/21)</td></tr><tr><td>POMCp110&#x003b1; null</td><td align="char">&#x0002b;3.2 &#x000b1; 1.4<sup>&#x02217;</sup> (13)</td><td align="char">&#x0002b;1.0 &#x000b1; 0.5<sup>&#x02217;</sup> (13)</td><td align="char">&#x0002b;6.3 &#x000b1; 1.9 (7/13)</td><td align="char">&#x0002b;2.2 &#x000b1; 0.5 (7/13)</td></tr><tr><td>POMCp110&#x003b2; null</td><td align="char">&#x02212;2.1 &#x000b1; 1.1 (17)</td><td align="char">&#x0002b;0.1 &#x000b1; 0.4 (17)</td><td align="char">&#x02212;6.1 &#x000b1; 1.7 (7/17)</td><td align="char">&#x02212;1.2 &#x000b1; 0.5 (7/17)</td></tr><tr><td>POMC &#x0002b; TGX-221</td><td align="char">&#x02212;0.9 &#x000b1; 1.6 (11)</td><td align="char">&#x0002b;0.3 &#x000b1; 0.8 (11)</td><td>&#x02212;16.0 (1/11)</td><td>&#x02212;5.6 (1/11)</td></tr><tr><td>AgRP</td><td align="char">&#x02212;0.1 &#x000b1; 1.1 (7)</td><td align="char">&#x02212;0.5 &#x000b1; 0.8 (7)</td><td>N.R.</td><td>N.R.</td></tr><tr><td>AgRPp110&#x003b1; null</td><td align="char">&#x02212;1.2 &#x000b1; 0.9 (7)</td><td align="char">&#x02212;0.9 &#x000b1; 0.4 (7)</td><td>N.R.</td><td>N.R.</td></tr><tr><td>AgRPp110&#x003b2; null</td><td align="char">0.0 &#x000b1; 0.2 (7)</td><td align="char">&#x02212;0.3 &#x000b1; 0.4 (7)</td><td>N.R.</td><td>N.R.</td></tr><tr><td colspan="5"><hr/></td></tr><tr><td colspan="5">&#x0002b;Insulin</td></tr><tr><td colspan="5"><hr/></td></tr><tr><td>POMC</td><td align="char">&#x02212;4.4 &#x000b1; 1.1<sup>&#x02217;</sup> (19)</td><td align="char">&#x02212;2.2 &#x000b1; 0.7<sup>&#x02217;</sup> (19)</td><td align="char">&#x02212;7.1 &#x000b1; 1.1 (12/19)</td><td align="char">&#x02212;3.4 &#x000b1; 0.9 (12/19)</td></tr><tr><td>POMCp110&#x003b1; null</td><td align="char">&#x02212;0.6 &#x000b1; 0.3 (8)</td><td align="char">&#x02212;0.2 &#x000b1; 0.2 (8)</td><td>N.R.</td><td>N.R.</td></tr><tr><td>POMCp110&#x003b2; null</td><td align="char">&#x0002b;0.4 &#x000b1; 0.9 (9)</td><td align="char">&#x0002b;1.0 &#x000b1; 0.6 (9)</td><td>N.R.</td><td>N.R.</td></tr><tr><td>POMC &#x0002b;TGX-221</td><td align="char">&#x0002b;0.9 &#x000b1; 0.6 (8)</td><td align="char">&#x02212;0.1 &#x000b1; 0.2 (8)</td><td>N.R.</td><td>N.R.</td></tr><tr><td>POMC &#x0002b; PI-103</td><td align="char">&#x0002b;1.1 &#x000b1; 0.7 (7)</td><td align="char">&#x0002b;0.3 &#x000b1; 0.6 (7)</td><td>N.R.</td><td>N.R.</td></tr><tr><td>AgRP</td><td align="char">&#x0002b;1.4 &#x000b1; 0.5<sup>&#x02217;</sup> (13)</td><td align="char">&#x0002b;0.5 &#x000b1; 0.3 (13)</td><td align="char">&#x0002b;3.8 &#x000b1; 0.9 (4/13)</td><td align="char">&#x0002b;0.9 &#x000b1; 0.3 (4/13)</td></tr><tr><td>AgRPp110&#x003b1; null</td><td align="char">&#x02212;4.0 &#x000b1; 0.6<sup>&#x02217;</sup> (7)</td><td align="char">&#x02212;1.9 &#x000b1; 0.9 (7)</td><td align="char">&#x02212;4.0 &#x000b1; 0.6 (7/7)</td><td align="char">&#x02212;1.9 &#x000b1; 0.9 (7/7)</td></tr><tr><td>AgRPp110&#x003b2; null</td><td align="char">&#x02212;2.7 &#x000b1; 1.1<sup>&#x02217;</sup> (11)</td><td align="char">&#x02212;0.4 &#x000b1; 0.3 (11)</td><td align="char">&#x02212;5.2 &#x000b1; 1.4 (6/11)</td><td align="char">&#x02212;0.6 &#x000b1; 0.4 (6/11)</td></tr><tr><td>AgRP &#x0002b; wortmannin</td><td align="char">&#x02212;2.0 &#x000b1; 0.8<sup>&#x02217;</sup> (10)</td><td align="char">&#x02212;0.4 &#x000b1; 0.3 (10)</td><td align="char">&#x02212;4.2 &#x000b1; 0.8 (5/10)</td><td align="char">&#x02212;1.1 &#x000b1; 0.3 (5/10)</td></tr></tbody></table><table-wrap-foot><fn><p>Changes in membrane potential (Vm) and spike firing frequency are shown for control, p110&#x003b1;, or p110&#x003b2; null POMC and AgRP neurons. PI3K activity was also blocked in POMC and AgRP neurons by PI-103 (100 nM), wortmannin (100 nM), or the p110&#x003b2;-selective inhibitor TGX-221 (1 &#x003bc;M). Statistical significance (<sup>&#x02217;</sup>p &#x0003c; 0.05) was determined from all neurons (Total), irrespective of their response. For qualitative purposes only, responsive neurons were distinguished by a change in Vm greater than &#x000b1;2 mV. N.R., no apparent response. Numbers of cells are shown in parentheses. Data are expressed as mean &#x000b1; SEM.</p></fn></table-wrap-foot></table-wrap></floats-wrap></article> 